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Abbreviations 
AML     Acute myeloid leukemia 
ALL     Acute lymphoblastic leukemia 
B-ALL    B-cell ALL 
BCR    B-cell receptor 
BM    Bone marrow 
CD     Cluster of differentiation 
CLP     Common lymphoid progenitor 
CMP     Common myeloid progenitor 
CRLF2    Cytokine receptor like factor 2 
DP     Double positive 
DS-ALL    Down syndrome acute lymphoblastic leukemia 
ecotropic Env    Ecotropic envelope 
FACS     Fluorescence activated cell sorting 
fel env     Feline endogenous virus (RD114) envelope 
GMP     Granulocyte-macrophage progenitor 
HPC     Haematopoietic progenitor cell 
HPRT     Hypoxanthine-guanine phosphoribosyltransferase 
HRP     Horseradish peroxidase 
HSC     Haematopoietic stem cell 
i.v.     intravenous 
JAK     Janus kinase 
LMPP     lymphoid multipotent progenitor 
MEP     Megarkaryocyte-erythrocyte progenitor 
MPP     Multipotent progenitor 
NK     Natural killer 
NSG     NOD/SCID/γcnull 
qRT-PCR    Quantitative real time polymerase chain reaction 
PB     Peripheral blood 
P/S     Penicillin/streptomycin 
rpm     rounds per minute 
SCF     Stem cell factor 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  
STAT     signal transducer and activator of transcription 
TSLPR Thymic stromal lymphopoietin receptor 
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Zusammenfassung 
Der Begriff „Hämatopoese“ beschreibt den Prozess der Bildung der zellulären 
Blutbestandteile, welcher im Knochenmark stattfindet. Einen wichtigen Teil der Hämatopoese 
stellt die Bildung von reifen B-Zellen dar, welche sich in den sekundären lymphatischen 
Organen und dem peripheren Blut befinden und einen wichtigen Bestandteil des adaptiven 
Immunsystems darstellen. Die Entwicklung der B-Zellen wird über ein komplexes und streng 
reguliertes Netzwerk von verschiedenen Transkriptionsfaktoren kontrolliert, die zu 
unterschiedlichen Zeitpunkten exprimiert werden. Die B-Zell-Differenzierung wird außerdem 
über externe Faktoren wie die Zytokine reguliert. Diese aktivieren Rezeptoren an der 
Zelloberfläche, um Proliferation und Differenzierung zu induzieren oder Apoptose zu 
verhindern. Eine Deletion oder eine Mutation dieser Transkriptionsfaktoren oder der 
Komponenten der Rezeptor vermittelten Signaltransduktion kann zu einer Blockade in der 
Differenzierung und/oder zu einer veränderten Proliferation und folglich zu der Bildung von 
neoplastischen Krankheiten wie der B-Zellvorläufer akuten lymphoiden Leukämie (B-ALL) 
führen. 
Die Analyse von Patientenmaterial hat gezeigt, dass der CRLF2 Cytokinrezeptor, ein 
wichtiger Regulator der frühen B-Zellentwicklung, überexprimiert in B-ALL Fällen mit 
schlechter Prognose gefunden wurde. Eine hohe CRLF2 Expression tritt oft gemeinsam mit 
aktivierenden JAK2 Mutationen oder dimerisierenden Mutationen in CRLF2 auf. 
Bezeichnenderweise zeigten diese B-ALL Fälle auch sehr häufig genetische Veränderungen 
im IKZF1-Gen, welches für den Transkriptionsfaktor IKAROS kodiert, Dieser ist für die 
Differenzierung in die lymphoide Richtung notwendig und reguliert auch verschiedene, 
andere Stadien der B-Zellentwicklung. Das Wissen über das Zusammenspiel dieser zwei 
Arten von Mutationen in Verbindung mit Leukämie ist bisher lückenhaft, andererseits aber 
essentiell, um effektive Therapien für diese Gruppe von Risikopatienten zu etablieren. 
Ziel dieser Diplomarbeit war es daher, Mausmodelle zu entwickeln, um die Rolle dieser 
Faktoren in der Entstehung der B-ALL zu untersuchen. Die mutierten Gene wurden mittels 
retroviraler Vektoren in humane bzw. murine Stamm- und Vorläuferzellen (HSC/HPC) 
eingebracht. Die ersten Mausexperimente zeigten, dass die retrovirale Transduktion der 
HSC/HPC mit aktiviertem Jak2* sehr ineffizient war. Dies war wahrscheinlich aufgrund der 
Toxizität und/oder der Vektorgröße von Jak2* und der daraus resultierenden geringen viralen 
Vektortiter der Fall. Statt der Jak2* Kinase wurde daraufhin die Mutation CRLF2* zusammen 
mit der IKZFΔ6 Mutation in Primärzellen eingebracht. Hämatpoetische Stamm- und 
Vorläuferzellen konnten zu hohen Raten infiziert werden, aber der Anteil der Transgen 
exprimierenden Zellen ging im Blut und Knochenmark der transplantierten Mäuse im Laufe 
der Zeit stark zurück. Da auch die Mäuse mit doppelt infizierte (CRLF2*+IKZFΔ6) HSC/HPC 
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nach über drei Monaten noch keine B-ALL entwickelten, wurde eine weitere Studie 
begonnen, mit der der Einfluß eines zusätzlichen potentiellen Tumorsupressors (LNK) auf 
die Leukämieentstehung untersucht werden konnte. Es ist bekannt, dass LNK die Aktivität 
von JAK2 inhibiert und dass Lnk knock-out Mäuse eine hohe Anzahl an frühen B-
Zellvorläufern besitzen. Folglich wurde der Effekt von einer LNK Überexpression auf CRLF2* 
vermittelte Signaltransduktion analysiert. Dieser Assay zeigte, dass LNK Überexpression 
unter Zugabe von IL-3 die Proliferation von einer proB Zelllinie, vermutlich über die 
Inhibierung von Jak2, deutlich hemmt. Im Gegensatz dazu hatte die LNK Überexpression in 
Kombination mit CRLF2* und ohne IL-3 keine Auswirkung auf die Proliferation. Dies könnte 
ein Hinweis darauf sein, dass CRLF2* nicht nur über Jak2 wirkt, sondern auch andere 
Signalwege nutzt und dass eine Lnk Inaktivierung mit CRLF2* kooperiert, um Leukämie zu 
induzieren. Bezeichnenderweise haben erst kürzlich veröffentlichte Studien gezeigt, dass 
inaktivierende LNK Mutationen zusammen mit aktivierenden CRLF2 Mutationen in B-ALL 
auftreten. 
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Abstract 
„Haematopoiesis“ describes the process of the formation of cellular blood components that 
takes place in the bone marrow via several differentiation stages. The generation of mature 
B-cells is one important aspect of this process. They reside in the secondary lymphoid 
organs and the peripheral blood and represent an important part of the adaptive immune 
system. B-cell development is regulated via a complex and tightly regulated network of 
transcription factors that are expressed at different points in time. In addition, B-
lymphopoiesis is also tightly regulated by external factors such as cytokines, which activate 
cell surface receptors to stimulate proliferation, induce differentiation, or prevent apoptosis. 
Deletion or mutation of these transcription factors or components of the receptor signaling 
cascade may lead to a block of differentiation and/or aberrant proliferation, and consequently 
to the formation of neoplastic malignancies, such as B-cell progenitor acute lymphoblastic 
leukemia (B-ALL). Analysis of patient material has shown that the CRLF2 cytokine receptor, 
an important regulator of early B-cell development, is overexpressed in high-risk B-ALL 
cases. High CRLF2 levels are often accompanied by activating mutations in JAK2, or with 
dimerizing mutations in CRLF2. Significantly, these B-ALL cases also show a high incidence 
of genetic alterations in the IKZF1 gene, encoding of the transcription factor IKAROS, which 
is necessary for the differentiation into the lymphoid lineage, but which also regulates various 
stages of B-cell development. The interplay of these two types of mutations in leukemia 
induction is poorly understood, but essential for developing effective therapies in this high-
risk group of patients. 
Consequently, the aim of this thesis was to develop mouse models to analyze the role of 
these mutations in connection with B-ALL development. The mutated genes were transduced 
into human and murine stem and primary cells via retroviral vectors. The first mouse 
experiments showed that retroviral transduction of activated Jak2* into human CD34+ cells 
or murine haematopoietic stem or progenitor cells (HSC/HPC) was very inefficient. This was 
probably due to the toxicity and/or the large vector size of Jak2*, resulting in low viral vector 
titers. Consequently, a mutated CRLF2* was used instead of the Jak2* kinase to infect 
primary cells together with a dominant-negative IKAROS (IKZFΔ6). These HSC/HPC were 
infected at quite high rates, but the percentage of transgene expressing cells in the blood 
and bone marrow of transplanted mice decreased significantly over time. Due to the fact that 
mice that carried double-transduced (CRLF2* and IKZFΔ6) HSC/HPC for over three months 
and did not establish B-ALL, studies were initiated to investigate a potential tumor 
suppressor that may contribute to leukemia induction. LNK is known to inhibit JAK2 activity, 
and Lnk deficient mice show high levels of early B-cell progenitors. Consequently, the effect 
of LNK overexpression on CRLF2* mediated signaling was examined. This assay showed 
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that LNK overexpression in the presence of IL-3 significantly inhibits the proliferation of pro-
B-cells, presumably through inhibiting Jak2. In the absence of IL-3 and together with CRLF2* 
there was no visible effect on the proliferation behavior of the pro-B-cells, suggesting 
CRLF2* may signal through other pathways. This work suggests that Lnk inactivation may 
cooperate with CRLF2* to induce aberrant pro-B-cell proliferation. Significantly, recent 
studies have indeed uncovered LNK inactivation mutations in B-ALL in conjunction with 
CRLF2 activating mutations.  
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1 Introduction 
1.1 Haematopoiesis 
 
 
 
Figure 1 Simplified summary of the process of haematopoiesis. 
Haematopoiesis starts with the HSC: haematopoietic stem cell. LT-HSC: long-term haematopoietic stem cell; ST-
HSC: short-term haematopoietic stem cell; MPP: multipotent progenitor; LMPP: lymphoid multipotent progenitor 
CMP: common myeloid progenitor; MEP: megakaryocyte-erythrocyte progenitor; GMP: granulocyte-macrophage 
progenitor; CLP: common lymphoid progenitor. The figure has been simplified and modified according to 
Passegue et al., 2003; Cedar et al., 2011. 
The term „haematopoiesis“ describes the process of the formation of cellular blood 
components. During haematopoiesis everything starts with the haematopoietic stem cells 
(HSCs) in the bone marrow. The HSCs have two functions. First of all they are able to 
perform self-renewal, which means they produce new HSCs without differentiation (Seita and 
Weissman, 2010). Due to their pluripotency they also possess the ability to differentiate into 
the different cell types of the blood. The balance between self-renewal and differentiation is 
regulated via niches in the bone marrow (Orkin, 2000; Wilson and Trumpp, 2006). There are 
two different kinds of HSCs: long-term (LT)-HSCs and short-term (ST)-HSCs. LT-HSCs 
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possess the lifelong ability of self-renewal (Orkin, 2000), whereas the ST-HSC are able to 
perform self-renewal for about eight weeks (Morrison and Weissmann, 1994). 
During the process of haematopoiesis HSCs differentiate into the multipotent progenitors 
(MPPs), which give rise to the common myeloid progenitors (CMPs) or lymphoid multipotent 
progenitors (LMPPs) or common lymphoid progenitors (CLPs). The LMPPs as well as the 
CMPs can give rise to the granulocyte-macrophage progenitors (GMPs), which are able to 
differentiate into monocytes and granulocytes (Passegue et al., 2003; Cedar and Bergman, 
2011), which are part of the innate immune system. Additionally, CMPs are able to form 
erythrocytes and megakaryocytes via the megarkaryocyte-erythrocyte progenitors (MEPs). 
The differentiated megakaryocytes are responsible for the release of thrombocytes, whereas 
the erythrocytes are essential for the transport of oxygen in the blood. The CLPs on the other 
hand differentiate into the lineage restricted progenitors named pro-DC, pro-B and pro-T, 
which then form the dendritic, B- and T-cells (Laiosa et al., 2006), representing cells of the 
adaptive immune system. The decision whether CLPs form B- or T-cells is regulated by the 
localization of the cells. T-cells are produced in the thymus (Chung et al., 2003), while CLPs 
that remain in the bone marrow differentiate into the B-cell lineage. The B-cell progenitors 
leave the bone marrow before they are completely mature and migrate to the secondary 
lymphoid organs, such as the spleen and the lymph nodes.  
1.2 B-cell development 
The formation of B-cells takes place in the bone marrow, as described in 1.1, starting from 
the HSCs. Mature B-cells are formed through a complex process of differentiation stages. 
These stages are characterized by the expression of different lineage specific proteins on the 
cell surface (CD molecules). Using antibodies that selectively bind to these surface 
molecules and are coupled to fluorescence markers, it is possible to distinguish the different 
stages of B-cell development by their different patterns of surface markers expression via 
FACS analysis (Hardy et al. 1991; Perez-Vera et al., 2011). 
The HSCs, characterized by the expression of Sca and c-kit, differentiate into the LMPP 
population, which is defined by the occurrence of the cell surface markers Sca1 c-kit and 
FLT3, as depicted in Figure 2. The HSCs and the LMPPs form the LSK (Lin-Sca+c-kit+) 
population. The LMPPs, which in contrast to the HSCs also show FLT3 expression, 
represent the first population that is not able to differentiate into erythrocytes and 
megakaryocytes anymore (Buza-Vidas et al.,2011). The CLP population is identified by the 
expression of the IL-7R α-chain (Nutt and Kee, 2007). The CLPs can be divided into early 
and late CLPs, the latter of which express Ly6D and are specified to the B-cell lineage (Inlay 
et al., 2009). The CLPs are followed by the pro-B-cells, which are characterized by CD43 
expression, which is already present in the HSCs, as well as by CD19 and B220 expression 
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(Hardy et al., 2007). Subsequent differentiation stages are hallmarked by the accumulation of 
events leading to the formation of a functional B-cell receptor (BCR). 
 
Figure 2 Development and differentiation of B-cells. 
The figure shows the variable stages of B-cell differentiation. Additionally, the development of the BCR as well as 
the expression of different cell surface molecules, which are characteristic for the different stages, are shown. The 
figure is simplified and modified according to Hardy et al., 2007; Nutt et al., 2007; Welinder et al., 2011.  
The formation of the functional BCR is a complex process and characterizes several stages 
of B-cell development. The process of BCR formation starts in the pre-B-cells, which possess 
a preBCR. This preBCR possesses a heavy immunoglobulin chain (HC), which is formed by 
DHJH as well as VHDHJH rearrangement of the Igh locus. The DHJH rearrangement starts 
already in the pro-B-cell stage and is regulated via a complex containing Rag1 and Rag2 
proteins. The expression of the Rag1 and Rag2 gene is regulated among others via the 
important transcription factor IKAROS (Reynaud, 2008). After the rearrangement is 
terminated, a functional HC protein binds with a so-called surrogate light chain (sLC) to form 
the preBCR. Surface expression of this receptor represents the transition from the pro-B to 
the pre-B-cell phase. Surface expression of a functional preBCR stimulates proliferation, 
leading to the clonal expansion of the cells, but also triggers the stage-specific recombination 
of the two immunoglobulin LC loci (Igκ and Igλ). The recombination of the V and J fragments 
(VLJL rearrangement) leads to the expression of a functional LC and therefore to the 
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formation of the mature, surface BCR, which marks the crossing to the phase of immature B-
cells phase (Melchers et al., 2000). If the BCR on the immature B-cells do not recognize self-
antigen after several days in the blood and bone marrow, mature B-cells are formed. This 
happens via migration of the immature B-cells from the bone marrow to the secondary 
lymphoid organs, such as the spleen and lymph nodes. 
The main function of mature B-cells is the recognition of antigen and pathogens via the BCR 
and the consequent production of specific antibodies through a complex process. The 
production of these antibodies contributes to the control of the pathogen. Therefore, B-cells 
represent an important part of the humoral, adaptive immune response. 
1.2.1 Transcription factors 
In addition to extracellular cytokines, which bind to their specific receptors and induce signal 
cascades, there are intracellular transcription factors that play an important role in early B-
cell development. The activity of these transcription factors leads to the activation or 
inhibition of the gene expression of specific target genes, what regulates the process of 
differentiation.  
1.2.1.1 PU.1 
The SFPI1 gene encodes for the purine box factor 1 (PU.1). PU.1 is expressed in all states 
of B-cell differentiation at different levels (DeKoter et al., 2007). Sfpi1-/- mice die during 
embryogenesis, show severe defects in the lymphoid and myeloid lineage and possess 
neither fetal B-cells nor T-cells in the thymus (Scott et al., 1994; McKercher et al., 1996). 
Consequently it is assumed that there is a block before the CLP state in Sfpi1-/- mice and 
PU.1 expression plays an essential role in the MPPs, by regulating the differentiation in the 
lymphoid direction (DeKoter et al., 2002). 
1.2.1.2 E2A 
The TCF3 gene encodes for the E2A protein, which belongs to the Basic Helix Loop Helix 
(bHLH) protein family. TCF3 encodes for two different proteins: E47 and E12, which are 
made via alternative splicing. These proteins can form heterodimers with bHLH proteins. But 
E2A mainly functions as homodimer in the B-cell lineage (Kee et al., 2000).  
Tcf3-/- mice show a block at the pro-B-cell stage (Matthias and Rolink, 2005). These mice do 
not possess CD19 positive B-cells and lack the expression of B-cell specific genes such as 
Pax5, Rag1 and Rag2, which are necessary for the DHJH rearrangement and consequently 
no functional preBCR can be formed (Bain et al., 1994). 
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1.2.1.3 EBF1 
The early B-cell factor 1 (EBF1) is mainly expressed in pro, pre and mature B-cells. Ebf1-/- 
mice show a differentiation block at the early pro-B-cell stage as well as a reduced 
expression of B-cell specific genes such as Pax5 and of genes, which are important for the 
formation of the preBCR (Matthias and Rolink, 2005; Nutt and Kee, 2007). E2A and PU.1 
activate the expression of EBF1, whereas PAX5 represents a target gene of EBF1 (Lukin et 
al., 2008). EBF1 expression is activated by the interleukin-7 signaling pathway and is thought 
to be the key transcription factor that specifies B-cell lineage development (Busslinger et al., 
2000; Nutt and Kee, 2007). 
1.2.1.4 PAX5 
Expression of the paired homeodomain protein 5 (PAX5) gene starts in the pro-B-cells and 
its expression is not downregulated until the plasma cell state. Pax5-/- mice also show a block 
at the pro-B-cells stage as well as a loss of B-cell specificity. These cells are able to 
differentiate into other directions such as into NK cells. This shows that PAX5 is essential for 
the B-cell specific differentiation. The PAX5 gene is a target gene of E2A and EBF1, whereas 
the PAX5 protein itself regulates the expression of genes, which are important for the B-cell 
specific development such as CD19 (Nutt and Kee 2007). 
1.2.1.5 IKAROS 
The IKZF1 gene, which was of main interest during this thesis, encodes the zinc finger 
transcription factor IKAROS, which is an important regulator of lymphoid development and 
differentiation. Ikaros is a member of a family of zinc finger transcription factors that includes 
Helios, Aiolos, Eos and Pegasus. 
The Ikaros protein possesses 6 zinc fingers, four at the N-terminus, which are important for 
DNA binding, and two at the C-terminus, which are necessary for dimerization. Alternative 
splicing results in lots of different splicing variants (Molnar and Georgopoulos, 1994). Ikaros 
expression is found in cells of the myeloid as well as of the lymphoid lineage, but also in the 
HSCs and multipotent progenitors. Ikaros shows the highest homology to Aiolos and is able 
to form homodimers or heterodimers with Aiolos (Busslinger, 2004; John and Ward, 2011). 
Different mouse models with different mutant forms of Ikaros have shown that differentiation 
into CLPs is not possible without a functional Ikaros protein. Therefore, it has been 
postulated that Ikaros plays a role in the early multipotent progenitors influencing 
differentiation in direction of the lymphoid lineage (Busslinger, 2004). 
In Ikzf1-/- mice all B- and NK-cells as well as B-cell progenitors were lost, but T lymphocytes 
were still present (Wang et al., 1998). 
Ikaros also contributes to the formation of the BCR by regulating the expression of Rag1 and 
Rag2, which are responsible for the rearrangement of the heavy chain. In vitro experiments 
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have also shown that Ikaros downregulates the expression of the Igll1 gene, which encodes 
for λ5, as sLC that is part of the preBCR (Sabbattini et al., 2001). 
 
 
 
Figure 3 Primary structure of the Ikaros protein. 
IKAROS possesses six zinc fingers (Bercovich et al., 2008): four zinc fingers at the N-terminus that are 
responsible for DNA binding, whereas the two C-terminal zinc fingers mediate dimerization. Modified according to 
Mullighan et al., 2009. 
1.2.2 Cytokine and tyrosine kinase signaling 
As mentioned in 1.2, it has been shown that B-cell development is regulated and controlled 
by a variety of transcription factors and by the expression of different transmembrane 
receptors, which are involved in different signaling pathways (Busslinger, 2004). Cytokine 
receptors, such as Flt3 and IL7R, are one important system of regulation. Cytokines bind to 
these specific receptors, what leads to activation of signal cascades and therefore influences 
the survival, proliferation and differentiation of cells. These receptors can influence 
haematopoiesis in a negative and positive way and are expressed at different stages of 
haematopoiesis. 
1.2.2.1 Flt3 
 
 
Figure 4 The Flt3 tyrosine kinase. 
The Flt3 kinase is composed of an extracellular ligand-binding domain, a transmembrane domain, a 
juxtamembrane domain and two tyrosine kinase domains, which are connected by a kinase insert domain (KI). 
The figure is modified according to Takahashi et al., 2011. 
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The Flt3 gene encodes for the Flt3 transmembrane receptor, which belongs to the class III 
receptor tyrosine kinases (Takahashi, 2011). The extracellular N-terminus consists of five Ig-
like domains, which mediate the Flt3 ligand binding. The intracellular domain is composed of 
the juxtamembrane domain and two tyrosine kinase domains. They mediate signal 
transduction and are connected via a kinase insert domain (Small, 2006). 
Flt3 expression can be found in the early myeloid and lymphoid lineage (Maroc et al., 1993). 
It is not possible to detect Flt3 expression in the LT-HSCs, but it is already possible in the 
ST-HSCs, which shows that Flt3 expression leads to the loss of self-renewal capacity. Flt3 
expression is also detectable in the following LMPPs as well as in the CLPs. Its expression in 
the LMPPs directs B-cell specific development (Adolfsson et al., 2005; Buza-Vidas et al., 
2011). The expression of Pax5 in pro-B-cells terminates the Flt3 expression (Holmes et al., 
2006). 
The importance of the Flt3 receptor is evidenced by analysis of Flt3 ligand (Flt3L-/-) deficient 
mice. These mice have a significant decrease of pro- and pre-B-cells in the murine bone 
marrow as well as a decrease of myeloid progenitors, NK cells and dendritic cells (McKenna 
et al., 2000). Flt3 knockout (Flt3-/-) mice also showed a reduced number of early B-cell 
progenitors (Matsumura et al., 2008). This has shown that the Flt3 receptor and ligand are 
essential for the formation of the CLPs and consequently the formation of pro- und pre-B-
cells.  
Binding of the Flt3 ligand to Flt3 leads to homodimerization of two Flt3 receptor tyrosine 
kinases within the membrane. Consequently, the two cytoplasmic domains gain close 
proximity and are able to transphosphorylate their juxtamembrane domains. This leads to 
conformational changes and activation of the receptors. The autophosphorylation of the 
kinase domains allows the binding of adaptor molecules and leads to the activation of signal 
cascades via phosphorylation of effector molecules. Flt3 signaling is involved in important 
pathways such as the PI3K/AKT, Ras/MAPK and JAK/Stat5 pathways. These pathways are 
involved in apoptosis, proliferation and differentiation, and therefore Flt3 possesses an 
oncogenic potential (Parcells et al., 2006; Matsumura et al., 2008). 
1.2.2.2 Cytokine signaling in early B-cell development 
There are two cytokines, interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP), which 
play an essential role at early stages of B-cell differentiation. These two cytokines use two 
distinct receptors, the IL-7 receptor (IL-7R) and the TSLP receptor (TSLPR), but share a 
common subunit. Both receptors belong to the Type 1 cytokine receptor family. The IL-7R 
represents a heterodimeric receptor consisting of two different protein chains: the IL-7R α-
chain and the γC-chain. The α-chain together with the “cytokine-receptor-like factor 2” 
(CRLF2) chain form the TSLPR, as depicted in Figure 5 (Park et al., 2000). The binding of IL-
7 is mediated by the extracellular part of the IL-7R α-chain, whereas the γC-chain increases 
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the binding affinity. The γC-chain is also involved in the formation of interleukin receptors for 
IL-2, IL-4, IL-9, IL-15 and IL-21 (Milne and Paige, 2006; Palmer et al., 2008). The CRLF2 
chain does not show a high affinity for TSLP, but the affinity increases together with the IL-
7R α-chain. 
 
 
Figure 5 The IL-7R and the TSLPR. 
It is visible in (a) that the ligand TSLP binds to a receptor, which consists of the TSLPR chain and the IL-7R α-
chain. Binding of TSLP leads to activation of dendritic cells in humans and to activation of the B-cell development 
in mice. Figure (b) shows that IL7 binds to a receptor consisting of the IL-7R α-chain as well as of a γC-chain. 
Binding of IL7 leads to activation of T cell development in humans and to activation of T and B-cell development 
in mice Leonard et al., 2002. 
The IL-7R is first detected in the CLP compartment and continues to be expressed during T-
cell development in T-cell progenitors and mature T-cells. During B-cell development, IL-7R 
is found in pro-B- and early pre-B-cells, whereas it cannot be found anymore at the transition 
from pre-B- to IgM+ B-cells (Sudo et al., 1993). Much evidence supports the hypothesis that 
its expression induces the B-cell development, and thereby inhibits myeloid differentiation 
(Kondo et al., 1997). Looking at the IL-7R-/- and IL7-/- mouse models it is possible to 
recognize the importance of the IL-7R for the B-cell development. No normal B-cell 
development is possible and a block at the CLP stage is visible in the knock-out mice 
(Peschon et al., 1994; von Freeden-Jeffry et al., 1995). Compared to wild-type mice, these 
knock-out mice contain just 1/3 of the CLP population, which is not able to differentiate into 
mature B-cells (Dias et al., 2005). Consequently, it has been postulated that the block 
probably takes place at the transition from the early (Ly6.D-) to the late (Ly6.D+) CLPs, 
whereas the down regulation of transcription factors such as EBF1 contributes to the 
differentiation arrest (Tsapogas et al., 2011). 
The IL-7R is involved in the activation of several signaling pathways that are important for 
survival, proliferation and differentiation of the B-cell progenitors. The α- and γ-chain of the 
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IL-7R do not possess tyrosine kinase activity, but they are able to activate associated 
kinases and recruit SH2-domain containing adaptor molecules. The IL-7R is involved in 
signaling pathways such as the PI3K/AKT and the MAPK/ERK pathway (Corfe and Paige, 
2012). It also activates the JAK-STAT pathway. The α- and γ-chains are associated with a 
JAK3 and JAK1, respectively. Binding of IL7 ligand leads to dimerization of the α- and γ-
chain, which increases the proximity of the JAK kinases. This results in transphosphorylation 
and an increased kinase activity. The STAT proteins are recruited and phosphorylated, what 
leads to their dimerization. The STAT dimer is then able to translocate into the nucleus and 
to regulate the expression of target genes (Nosaka et al., 1995; Rodig et al., 1998; Rawlings 
et al., 2004). 
The TSLPR signaling pathways are less understood. These receptors also do not possess 
any intrinsic catalytic activity but lead to STAT5 activation. The opinions about the 
mechanism of STAT5 activation are controversial. On the one hand it is postulated that 
STAT5 activation is independent of JAK proteins, whereas on the other hand it has been 
shown that TSLP mediated signaling requires JAK1 and JAK2 (Isaksen et al., 1999; Levin et 
al., 1999; Rochman et al., 2010). The ligand of this heterodimeric receptor complex is TSLP, 
which is related to IL-7 and is produced by epithelial cells to activate dendritic cells, induce 
inflammation and allergic responses (Russell et al., 2009). It is also known that TSLP is 
important for the proliferation, survival and differentiation of B-cell progenitors. CRLF2 is 
found on many cells of the immune system such as dendritic cells, T- and B-cells as well as 
on monocytes and mast cells.  
Concentrating on B-cells, it is known that TSLP drives the B-cell progression towards IgM+ B-
cells via mechanisms that are different from the IL-7 mediated mechanism. It has been 
postulated that TSLP is particularly active on pro-B-cells. But TSLPR-/- mice show a normal 
B-cell development and possess a normal population of IgM+ cells (He and Geha, 2010).  
The opinions concerning the definitive role of CRLF2 for B-cell development are 
controversial. On the one hand it has been postulated that TSLP overexpression leads to the 
suppression of the B lymphocytes population and is not able to restore the B-cell 
differentiation in IL7-/- and Flt3-/- mouse models (Jensen et al., 2007). On the other hand, 
other groups have shown that TSLP overexpression might restore the B-cell population in IL-
7 deficient mice (Chappaz et al., 2007). 
1.2.2.3 JAK proteins 
As already mentioned it is known that different signaling pathways play an important role 
during the process of haematopoiesis. These pathways consist of growth factor or cytokine 
binding to a cytokine receptor on the cell surface, followed by signaling cascades, which 
finally lead to the regulation of the expression of target genes. These cytokine receptors do 
not possess an intrinsic catalytic activity and are therefore associated with intracellular 
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tyrosine kinases such as the JAKs. The occurrence of activating mutations and translocation 
in these tyrosine kinases lead to constitutive signaling and enhanced proliferation and 
therefore to the development of haematologic malignancies (Khwaja, 2006; Gery et al., 
2009). 
There are four different JAKs found in mammalians: JAK1, JAK2, JAK3 and TYK2. Of these 
four different JAK proteins, JAK2 is most frequently mutated in haematopoietic malignancies. 
Looking at Jak2-/- mice, the specific importance of JAK2 becomes clear. These mice die at an 
embryonic age of 12 days, due to the failure of definitive erythropoiesis (Neubauer et al., 
1998). Although conditional knock-out mice have been generated, their role in adult 
hematopoiesis has only recently been studied (Grebien et al., 2008; Hantschel et al., 2012). 
Jak2 is known to be pivotal in relaying signals of myeloid-specific cytokines (IL-3, GM-CSF, 
G-CSF), but may only be important in very early stages of lymphoid differentiation. In 
contrast, drastic defects in the development of lymphoid cells are visible in Jak3-/- mice. They 
possess a smaller spleen, thymus and lymph nodes and show severe defects in T- and B-
cell development (Aringer et al., 1999). 
The best understood signaling pathway of JAK proteins is that involving the STAT proteins. 
In this important pathway, as depicted in Figure 6, cytokine-receptor binding leads to 
receptor multimerization and juxtaposition of their associated JAK proteins. This is followed 
by the autophosphorylation and therefore activation of the receptor-associated JAKs on their 
tyrosine domain. The phosphorylated JAKs are then able to phosphorylate the intracellular 
part of the cytokine receptor. These phosphorylated sites represent a docking site for 
signaling proteins such as the STAT proteins, which are located unphosphorylated and 
monomeric in the cytoplasm upon activation. The STATs are then phosphorylated by the 
JAKs and consequently are able to dimerize via their SH2-domain. The resulting homo- or 
heterodimers enter the nucleus via importinα-5 dependent mechanism to regulate 
transcription of target genes (Ward et al., 2000). To prevent unregulated signaling, the JAK-
STAT pathway is controlled via several processes such as receptor internalization and 
factors such as tyrosine phosphatases, PIAS (protein inhibitor of activated STAT) and SOCS 
(suppressor of cytokine signaling) proteins (Khwaja, 2006). 
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Figure 6 The JAK-STAT pathway. 
Binding of a cytokine to the cytokine receptor leads to autophosphorylation of the JAK proteins. They then 
phosphorylate the receptor, which leads to binding and phosphorylation of the STAT proteins. Consequently, the 
STATS form dimers and are able to enter the nucleus, where they regulate target gene expression. Modified 
according to O’Neill et al., 2006. 
The fact that the JAK-STAT pathway is used by a wide range of factors, including receptor 
tyrosine kinases such as Flt3 that are important for haematopoiesis combined with the fact 
that many key genes contain STAT responsive elements shows its importance and necessity 
for functional haematopoiesis. 
The JAK proteins show a unique structure among tyrosine kinases. The primary structure of 
JAK2, as depicted in Figure 7, shows that the protein possesses the JH1 domain at the 
carboxy terminus, which contains the catalytic kinase domain and the JH2 domain, which 
represents the pseudokinase domain. The pseudokinase domain, which is catalytically 
inactive, is thought to negatively regulate the catalytic activity of the kinase domain and may 
mediate protein-protein interactions. Binding to the intracellular part of the cytokine receptors 
is mediated via the FERM domain.  
 
 
Figure 7 Primary structure of JAK2. 
The primary structure of JAK2 shows the N-terminal FERM domain, the SH2 domain as well as the pseudokinase 
domain (JH2) and the kinase domain (JH1) at the C-terminus. Several known point mutations are indicated. 
Modified and simplified according to Mullighan et al., 2009. 
Next to the main proteins involved in the JAK-STAT pathway, there are other effector 
proteins that show an impact on some of the events during the JAK-STAT pathway. One 
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class of these kind of proteins represents the „SH2B/LNK/APS family“ (Rawlings et al., 
2004). Due to their possession of a SH2 domain they also present targets of JAK 
phosphorylation. 
1.2.3 LNK 
LNK is an adaptor protein, which is mainly expressed in haematopoietic cells such as in the 
lymphocytes. It represents a 68 kDa protein and its NH2-terminal domain contains a proline 
rich region. Furthermore, the protein contains a PH domain and a SH2 domain at the C-
terminus. LNK plays an important role in a variety of signaling pathways, starting from growth 
factor and cytokine receptors, such as c-kit, erythropoietin receptor, and JAK2 associated 
receptors. With its SH2 domain it is able to bind phosphorylated tyrosines of various 
signaling molecules and thereby inhibits them. For example, LNK can bind and inhibit 
mutated tyrosine kinases, as visualized in Figure 8 whereas a mutation in its SH2 domain 
results in an abolishment of its inhibitory activity (Rudd, 2001). 
To access the importance of this protein, the group of Takaki generated Lnk knock-out mice 
(Lnk-/-) and showed that there is a function for Lnk in limiting B-lymphopoiesis and to regulate 
the responsiveness to growth factor stimulation (Takaki et al., 2000). They showed that 
whereas the T-cell development was unaffected, B220loIgMhi cells, which represent 
immature, newly generated B-cells accumulated in the spleens of Lnk-/- mice. The B220loIgM- 
cell population was also increased in the spleens of these mice, which is quite surprising, 
because normally this kind of progenitor population only occurs in the bone marrow. In the 
bone marrow the pro- and pre-B-cells were also proportionally increased, which reflects an 
enhanced proliferation of B-cell progenitors. The responsible mechanism for the B-cell defect 
has been postulated to be disruption of IL-7R signaling, although molecular and biochemical 
studies to demonstrate this have not been performed. 
It has also been shown that Lnk plays a role in HSC quiescence and self-renewal as well as 
in the haematopoietic progenitors. The balance between cell cycle quiescence, self-renewal 
and proliferation plays an important role in HSCs. The process of quiescence and self-
renewal is regulated via the binding of TPO to the Mpl receptor, what leads to 
phosphorylation of JAK2 and consequently the phopshorylation of the receptor. This allows 
the binding of Lnk. It has been proven that Lnk directly binds to phosphorylated tyrosine 
residues of JAK2 and represents a negative regulator of JAK2 in the HSCs. Therefore, Lnk 
knock-out leads to an increased activation of JAK2, particularly in the response to TPO, and 
as consequence to an expanded HSC pool, consisting of an increased number of quiescent 
cells (Bersenev et al., 2008). A defect in the erythroid compartment has also been attributed 
to defects in erythropoietin (Epo) receptor signaling (Tong et al., 2005). 
Furthermore, it has been postulated that Lnk plays a role in myeloid progenitor cells by 
binding directly to and interacting with several receptors, such as FLT3, PDGFR and FMS. 
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Lnk also negatively regulates the SCF/c-kit signaling pathway in haematopoietic progenitors. 
Their number is increased in Lnk-/- mice due to the fact that there is a higher growth signaling 
through the c-kit receptor in Lnk-/- mice. Binding of SCF to the c-kit receptor leads to the 
recruitment and tyrosine residue phosphorylation of different proteins such as Gab2. Gab2 
then leads to the activation of the MAPK signaling pathway, for example. LNK in this 
correlation leads to inhibition of the c-kit mediated proliferation by inhibiting the 
phosphorylation of Gab2 and therefore inhibiting the activation of the MAPK pathway, as 
shown in Figure 8. The haematopoietic progenitor cells compartment increases in the 
absence of LNK and the cells show an enhanced repopulating ability due to an enhanced c-
kit signaling. (Takaki et al., 2002).  
 
 
 
Figure 8 The role of LNK in different signaling pathways. 
It has been shown that the adaptor protein LNK inhibits the activity of Gab2 as well as of Jak2, consequently 
inhibiting the activation of the MAPK/ERK and PI3K/AKT pathway in haematopoietic progenitor cells. An increase 
of SCF, TPO and EPO mediated signaling leads to enhanced proliferation of the progenitor cells in the absence of 
LNK (Takaki et al., 2002). Figure adapted according to Devalliere et al., 2011. 
1.2.4 Leukemia and B-ALL 
1.2.4.1 Leukemia 
Cancer of the blood and bone marrow is called leukemia. This kind of cancer is characterized 
by an increased number of leukocytes in the bone marrow, spleen and peripheral blood, 
which is the result of a deregulated proliferation and differentiation. 
Two kinds of leukemia can be distinguished: the acute and the chronic form. The chronic 
form is characterized by no or little block in differentiation, which leads to a less drastic or 
slower progression of the disease. The acute leukemia is defined by a significant proliferation 
of inoperable progenitors blocked in differentiation. These aberrant progenitors overgrow the 
functional cells and destroy the function of the immune system as well as several organs. 
According to the affected cell lineage, acute myeloid leukemia (AML) and acute 
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lymphoblastic leukemia (ALL) can be distinguished. In contrast to the AML, which is mainly 
found in adults, ALL mainly occurs in children of 2-4 years (Gilliland and Tallman, 2002).  
Transformation to a preleukemic or leukemic cell takes place at the level of the HSCs and/or 
progenitors. These changes include, as Figure 9 shows, increased self-renewal ability, as 
well as the block of differentiation and apoptosis. Furthermore, these cells do not show 
controlled proliferation and react differently to growth and anti-growth signals. Additionally, 
the telomerase activity is changed in leukemic cells, which means that ageing is retarded in 
these cells (Pui et al., 2004). 
 
 
Figure 9 The leukemic cell. 
The properties, which differ between a normal HSC or haematopoietic progenitor and a leukemic cell, are shown. 
Modified according to Pui et al., 2004. 
Genetic changes lead to the transformation of normal haematopoietic progenitor cells to 
leukemic cells. But at least two mutations are necessary for this kind of transformation. Class 
1 mutations, as for example mutations of tyrosine kinase receptors Flt3 and c-kit or of a 
proto-oncogene such as Ras, lead to a survival and proliferation advantage of the mutated 
cell. Class 2 mutations, in contrast to class 1 mutations, block the differentiation and increase 
the self-renewal capacity of the cell. This second class of mutations generally affects genes 
encoding transcription factors. The two classes of mutations cooperate to contribute to 
leukemia formation (Graf and Beug, 1983; Dash and Gilliland, 2001). 
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1.2.4.2 B-ALL 
1.2.4.2.1 B-ALL and BCR-ABL1 
Progenitor or precursor B-cell (B-)ALL represents more than 80% of the lymphoid leukemias 
in children and over 75% in adults. With a cure rate of 80% in children, a big success against 
this disease has already been reached. This means that ALL is actually curable, but 20% of 
the B-ALL cases are resistant, representing cases of high-risk B-ALL. Consequently, ALL still 
represents the second leading cause of pediatric cancer death (Mullighan et al., 2009).  
B-ALL is a clonal disease, which arises from a single cell and leads to the accumulation of 
blast cells resulting in the suppression of normal haematopoiesis and infiltration of various 
extramedullary sites (Reynaud, 2008; Cobaleda and Sanchez-Garcia, 2009). It is assumed 
that the development of pediatric B-ALL is initiated by chromosomal changes, such as 
rearrangements or translocations, or mutations in HSC/HPC that reside in the bone marrow 
or fetal liver.  
Consequently the identification of recurrent chromosomal translocations is of prognostic 
importance for ALL cases. The most common chromosomal translocation generates TEL-
AML1 (ETV6-RUNX1), which is present in 25% of pediatric B-ALLs. Another fusion 
transcript, which occurs in B-ALL, is BCR-ABL, which is present in 33% of adult B-ALL and in 
5% of childhood B-lineage ALL. A translocation between chromosome 22 and 9 results in the 
formation of the BCR-ABL1 fusion gene. This gene encodes for the oncoprotein BCR-ABL 
that represents a constitutively active tyrosine kinase, which perturbs several signaling 
pathways such as the MAPK, JAK/STAT5 and Myc pathways. This leads to an uncontrolled 
cell proliferation and reduced apoptosis in early leukemogenesis. The outcome of BCR-ABL 
positive ALL is quite poor (Armstrong and Look, 2005; Piccaluga et al., 2007). High-risk 
patients without BCR-ABL1 translocation show comparable gene expression patterns 
compared to the patients with this chromosomal translocations (Den Boer et al., 2009; 
Mullighan et al., 2009). These BCR-ABL1 negative cases with a comparable expression 
pattern represent the majority of high-risk B-ALL cases. Analysis of patients’ material of 
these cases resulted in the identification of among others CRLF2 rearrangements, JAK2 
mutations, IKZF1 deletions and LNK deletions (Hertzberg et al., 2010; Roberts et al., 2012). 
1.2.4.2.2 CRLF2* and JAK2* in B-ALL 
It has been postulated that genetic alterations at the CRLF2 locus, such as DNA copy 
number alterations, CRLF2 point mutations, as well as deletions or translocations upstream 
of CRLF2, lead to the overexpression of this receptor and may contribute to the formation of 
malignancies such as B-ALL. The overexpression of CRLF2 seems to occur only in B-ALL 
cases without BCR-ABL chromosomal translocations. It is known that in 7% of all B-ALL 
cases grouped together, there is a CRLF2 overexpression, whereas CRLF2 overexpression 
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is present in 50% of Down syndrome acute lymphoblastic leukemia (DS-ALL). Additionally, a 
point mutation of CRLF2 could be found in 10% of the CRLF2 overexpressing patients, with 
a F232C point mutation being one of the most frequent (Hertzberg et al., 2010). 
But it is also important to notice that CRLF2 overexpression alone is not sufficient to 
transform cells (Hertzberg et al., 2010; Roll and Reuther, 2010). It is postulated that due to 
the fact that CRLF2 possesses a Jak-binding Box 1 motif, it may be used as a scaffold for 
activated JAK2 (Mullighan et al., 2009; Yoda et al., 2010; Harvey et al., 2010). 
JAK2 also plays a role in acute lymphoblastic leukemia. Activating JAK2 mutations have also 
been found in high risk ALL (Mullighan et al., 2009). These mutations mainly occur in the 
highly conserved kinase and pseudokinase domain, as depicted in Figure 10, and result in a 
constitutive JAK-STAT signaling. It is known that 10% of all high-risk pediatric B-ALL show 
JAK mutations. Furthermore, it has been shown that there are JAK2 mutations in about half 
of the cases with CRLF2 overexpression in DS-ALL. 70% of the cases overexpressing 
CRLF2 in B-ALL also show JAK2 mutations (Mullighan et al., 2009). In contrast to JAK2 
mutations identified in myeloproliferative neoplasia (MPN), which is primarily a V617F 
mutation within the JH2 domain, the most common mutation in B-ALL is the R683G 
missense mutation (Jak2*), also occurring in the pseudokinase domain, which may result in 
the loss of the inhibitory activity of the pseudokinase domain, as depicted in Figure 10. This 
kind of mutation has also been found in patients’ samples of BCR-ABL1-negative cases, 
occurring together with CRLF2 rearrangement and IKZF1 deletion (Roberts et al., 2012). 
 
 
 
Figure 10 Primary structure of JAK2. 
The primary structure of JAK2 shows the N-terminal FERM domain, the SH2 domain as well as the pseudokinase 
domain (JH2) and the kinase domain (JH1) at the C-terminus. Several known point mutations are indicated. The 
R683G missense mutation was used for this thesis. Modified and simplified according to Mullighan et al., 2009. 
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1.2.4.2.3 B-ALL and IKZF1 
Genome-wide studies of over 200 children with B-ALL showed that genetic alterations of 
IKZF1 are associated with a very poor outcome in B-cell progenitor ALL (Mullighan et al., 
2009). This transcription factor plays an important role in high-risk ALL as Mullighan and 
others have shown that its deletion is frequent in BCR-ABL1-positive ALL: present in 80% of 
all the cases, but also in BCR-ABL-negative ALL (Figure 12). Overexpression of the 
dominant negative IKZFΔ6 has been found in 40% of adult pre-B-cell ALL (Rebollo and 
Schmitt, 2003). This isoform of Ikaros lacks all N-terminal, DNA-binding zinc fingers and is 
therefore not able to bind DNA. It is only located in the cytoplasm and not in the cell nucleus. 
This short isoform acts as a dominant negative, which inhibits the binding of the functional 
isoforms to the DNA and therefore prevents the normal, regulatory function of the Ikaros 
proteins (Rebollo and Schmitt, 2003).  
The similarity of the gene-expression signatures of BCR-ABL-negative ALL with IKZF1 
mutation and BCR-ABL-positive ALL raises the possibility that patients with BCR-ABL 
negative ALL and IKZF1 mutations might have activating mutations in tyrosine kinases 
(Martinelli et al., 2009; Mullighan et al., 2009). This hypothesis was born out in several 
studies showing coincident JAK2 mutations and IKZF1 deletions within this high-risk group 
(Mullighan et al., 2009). More recently, using “next-generation sequencing,” activating kinase 
mutations have been found in all 15 BCR-ABL1-negative ALL cases (Roberts et al., 2012). 
Whereas the majority has previously described CRLF2 or JAK2 mutations, mutations in the 
IL-7R or FLT3 were also found, as well as translocations leading to the constitutive activation 
of ABL, PDGFR, or EPOR. This work provides strong evidence that high-risk B-ALL is driven 
by activated tyrosine kinase pathways, but nevertheless many questions remain. What is the 
function of Ikzf1 deletion, a common feature of most (but not all) kinase-activated B-ALL? 
Can kinase inhibitors be used to effectively treat this patient pool and what are the pivotal 
downstream effectors?  
 
 
Figure 11 Primary structure IKZFΔ6 
IKAROS possesses six zinc fingers (Bercovich et al., 2008): four zinc fingers at the N-terminus that are 
responsible for DNA binding, whereas the two C-terminal zinc fingers mediate dimerization. The dominant-
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negative isoform IKΔ6(IK6) lacks exon three to six and therefore all N-terminal zinc fingers. The black arrows 
indicate point mutations of IKZF1. Modified according to Mullighan et al., 2009. 
In summary, molecular analysis of high-risk B-ALL has identified a common set of genetic 
mutations that are implicated in disease progression. The first shared feature is high 
expression of CRLF2, found in 7% of all B-ALL (and 50% of DS-ALL). At least two unique 
mechanisms are used to promote signaling through CRLF2: activating mutations in CRLF2 
itself (e.g F232C, leading to dimerization) or JAK2 mutations (e.g R683G, presumably 
resulting in inactivation of inhibitory sequences). These two mutation types only account for 
circa 70 to 80% of these patients, thus other mechanisms are probably at play. In light of the 
fact that Lnk is a known inhibitor of JAK2 signaling and its disruptions leads to the 
accumulation of early pro-B-cells, we postulate that Lnk inactivation may also contribute to 
disease progression. The final shared feature is the disruption of the IKZF1 gene, in many 
cases leading to the expression of a dominant negative transcription factor. The importance 
of this deletion is not known, but it presumably inhibits B-cell development at the proB stage. 
Why this mutation is so specific for high-risk ALL with tyrosine kinase mutations remains 
unclear. 
 
 
 
Figure 12 Selected mutations occurring in B-ALL. 
Overexpression of CRLF2 as well as JAK2, CRLF2 and IKZF mutations contribute to the formation of high-risk B-
ALL. The adaptor protein LNK might also play a role in the disease formation. Modified according to C.Stocking. 
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2 Aim of this work 
It is known that signaling via CRLF2 and the associated JAK2 proteins is important for B-cell 
proliferation, whereas IKAROS is essential for B-cell differentiation. Deletion or mutation of 
these transcription factors or components of the receptor signaling cascade may lead to a 
block of differentiation and/or aberrant proliferation, and consequently to the formation of 
neoplastic malignancies, such as B-cell progenitor acute lymphoblastic leukemia (B-ALL). 
Analysis of patient material has shown that the CRLF2 cytokine receptor is overexpressed in 
high-risk B-ALL cases often accompanied by activating mutations in JAK2. These B-ALL 
cases also showed genetic alterations of the transcription factor IKAROS. The interplay of 
these two types of mutations in leukemia induction is poorly understood, but essential for 
developing effective therapies in this high-risk group of patients. 
It was the aim of this work to develop mouse models to analyze the effects of different 
combinations of these mutated factors in murine and human primary cells and to determine 
their contribution to the formation of B-ALL. In a first set of experiments, two different 
approaches were used to infected human CD34+ HSC/HPC with retroviral vectors 
expressing Jak2* and IKZFΔ6 to determine which approach leads to the highest engraftment 
and infection of human cells in immune deficient NSG mice. Additionally, murine HSC/HPC 
isolated from bone marrow (BM) were infected either with Jak2* or CRLF2* together with 
IKZFΔ6 constructs to determine if one of these combinations contributes to B-ALL formation. 
LNK is known to inhibit JAK2 activity, and Lnk deficient mice show high levels of early B-cell 
progenitors. Additionally, it was postulated that its inactivation might also contribute to B-ALL 
formation, possibly by augmenting CRLF2 or JAK2 signaling. Consequently, the effect of 
LNK overexpression on CRLF2* mediated signaling and following proliferation of pro-B-cells 
was analyzed in vitro as preliminary study for probable following in vivo experiments. 
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3 Material and methods 
3.1 Material 
All laboratory-ware was obtained, if not noted otherwise, by the companies Merck 
(Darmstadt), Roth (Karlsruhe), Sigma-Aldrich (Munich) and Serva (Heidelberg). 
If not named otherwise, plastic-ware of the companies Becton Dickinson (Heidelberg), 
Sarstedt (Nümbrecht) and TPP (Trasadingen, Switzerland) was used. 
 
3.1.1 Equipment 
Biological safety cabinets Herasafe Thermo Scientific 
(Karlsruhe) 
Centrifuge Allegra X12R Beckmann Coulter 
(Krefeld) 
Desk centrifuge 5415D      Eppendorf (Hamburg) 
Electrophoresis chamber (DNA) Perfect Blue Mini S   PeqLab Biotechnologie
         (Erlangen) 
Electrophoresis system (Protein) Mini-PROTEAN Cell  Bio-Rad (Munich) 
Film processor AGFA Classic EOS     Siemens (Erlangen) 
Flow Cytometer FACSCanto Becton Dickinson 
(Heidelberg) 
Flow Cytometer FACSAria Becton Dickinson 
(Heidelberg) 
Gel documentation (DNA) BioDoc Analyze    Biometra (Göttingen) 
Heat block Thermomixer compact     Eppendorf (Hamburg) 
Hemavet Drew Scientific (Cumbria, 
UK) 
Incubator Hera Cell 150      Heraeus (Hanau) 
Lab balance PG503-S DeltaRange     Mettler Toledo (Gießen) 
Light Cycler 1.5       Roche (Mannheim) 
Magnetic stirrer RCT basic      IKA-Werke (Staufen) 
Microscope Zeiss IM       Zeiss (Oberkochen) 
Power supply power supply  
pH meter        Schott (Mainz) 
Photometer Nanodrop Spectrophotometer ND-100 New Brunswick Scientific 
(Edison, USA) 
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Pipettes (20µl, 200µl, 1000µl) Gilson (Middleton, USA) 
Protein blotting equipment Mini Trans-Blot Cell   Bio-Rad (Munich) 
Shaking incubator innova 4000     New Brunswick Scientific
         (Edison, USA) 
Sonificator Bioruptor Diagenode (Liège, 
Belgium) 
Vortex mixer Vortex-2 Genie                                                 Scientific Industries  
(Bohemia, USA) 
Water bath Typ 1008                                                              GFL (Burgwedel) 
X-ray film cassette                                                                  Rothaar & Schröder 
(Heidelberg) 
3.1.2 Software 
FACSDiva software version 4.2.2    Becton Dickinson (Heidelberg) 
Light Cycler Software 5.32     Roche (Mannheim) 
Biodoc 1.8.12.4      Biometra (Göttingen) 
Nanodrop ND-1000 V3.7.1     Thermo Scientific (Karlsruhe) 
3.1.3 Kits 
DNA Gel Extraction Kit     Millipore (Schwalbach) 
RNeasy Mini Kit      QIAGEN (Hilden) 
Plasmid Midi Kit      QIAGEN (Hilden) 
Plasmid Maxi Kit      QIAGEN (Hilden) 
QIAprep Miniprep Kit      QIAGEN (Hilden) 
ProFection® Mammalian Transfection System  Promega  
- Calcium Phosphate 
Lineage Cell Depletion Kit mouse  MACS Milteny Biotech (Bergisch-
Gladbach) 
Light Cycler® FastStart DNA Master  Roche (Mannheim) 
SYBR Green I Kit 
3.1.4 Media 
3.1.4.1 Bacteria culture 
LB medium: 10 g/L Bacto-Trypton (BD, Heidelberg); 5 g/L Bacto-yeast extract (DIFCO, 
Lawrence, USA); 10 g/L NaCl; pH 7,5 
LB agar: LB-medium; 15 g/L; agar (DIFCO, Lawrence, USA) 
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The media have been autoclaved before usage for 20min at 121°C. 100µg/ml of ampicillin 
were added to the LB medium as well as to the LB agar, after cooling down. 
 
3.1.4.2 Media, solutions and reagents for cell culture and mouse experiments 
Solutions and reagents for cell culture  
α-MEM Minimum Essential Medium alpha Modification PAA (Pasching, Austria) 
BSA (dry chemical) Bovine Serum Albumin   Sigma (Taufkirchen) 
Chloroquine (stock 25mM)     Sigma (Taufkirchen) 
Ciprobay (stock 2 mg/ml)     Bayer (Leverkusen) 
DMEM Dulbecco’s Modified eagle Medium   PAA (Pasching, Austria) 
FBS Fetal Bovine Serum     Lonza (Basel, Switzerland) 
FCS Fetal Calf Serum     Biochrom (Berlin) 
Glutamine (stock 200mM)     Sigma (Taufkirchen) 
HBSS Hank‘s Balanced Salt Solution (1x)   PAA (Pasching, Austria) 
Hepes (stock 1M)      PAA (Pasching, Austria) 
IMDM        Gibco (Darmstadt) 
MEM Alpha Modification (α-MEM)    PAA (Pasching, Austria) 
Methylcellulose M3231  StemCell Technologies (Grenoble, 
France) 
Penicillin/Streptomycin (stock 10000U/ml)   PAA (Pasching, Austria) 
Polybrene (stock 8mg/ml)     Sigma-Aldrich (Munich) 
Puromycin (stock 1µg/ml)     Sigma-Aldrich (Munich) 
Retronectin (stock 48µg/ml)  Takara Bio inc. (St.Germain en 
Laye, France) 
RPMI 1640 Cell culture medium    PAA (Pasching, Austria) 
SFEM        StemCell Technologies 
Sodium pyruvate (stock 100mM)    PAA (Pasching, Austria) 
Trypsin/EDTA (10 x; 0,5%/0,2% (w/v))   Biochrom (Berlin) 
 
IMDM:    IMDM powder solubilized in H2O to 310 mOS; pH 7,6 
10xPBS: 140mM NaCl; 3mM KCl; 10mM Na2HPO4; 1,5mM KH2PO4; pH 
7,4  
Cytokines 
Solubilized according to manufacturer instruction 
Human FLT3 (rhFLT3; stock 100ng/µl)     
Human Interleukin-11 (rhIL-11; stock 100ng/µl)  
Human stem cell factor (rhSCF; stock 100ng/µl) 
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Human Tpo (rhTpo; stock 20ng/µl) 
Human Interleukin-6 (rhIL-6; stock 20ng/µl)   
Murine Interleukin-3 (rmIL-3; stock 10ng/µl) 
Murine Interleukin-7 (rmIL-7; stock 20ng/µl)     
Murine stem cell factor (rmSCF; stock 100ng/µl)     
  
Cell culture media 
α-MEM medium (Bmi-Flt3) α-MEM; 10%(v/v) FCS (Biochrom); 4mM glutamine; 
1mM sodium pyruvate 
DMEM medium (HEK293T) DMEM; 10%(v/v) FCS (Lonza); 4mM glutamine; 
1mM sodium pyruvate; 20 mM HEPES 
DMEM medium (SC-1) DMEM; 10%(v/v) FCS (Biochrom); 4mM glutamine; 1 
mM sodium pyruvate 
Freezing medium   90%(v/v) FCS; 10%(v/v) DMSO 
IMDM medium IMDM; 5%(v/v) FCS; 1%(v/v) Penicillin/Streptomycin; 
4mM glutamine 
RPMI medium (Baf3) RPMI 1640, 10%(v/v) FCS, 4mM glutamine, 1mM 
sodium pyruvate 
SFEM medium (BM) SFEM; 4mM glutamine; 1mM sodium pyruvate; 
1%(v/v) Penicillin/streptomycin; cytokines (1:1000) 
 
Solutions and reagents for mouse experiments 
Baytril ®    BayerVital GmbH (Leverkusen) 
BD Pham Lyse™ (10 x)  Becton Dickison (Heidelberg) 
5-Fluoruracil (5-FU) (stock 50µg/µl) Medac (Hamburg) 
CALfix ProTaqs   Biocyc GmBH (Luckenwalde) 
3.1.5 Buffer 
3.1.5.1 DNA analytical methods 
6 x loading buffer   Fermentas (St, Leon-Rot) 
TAE (1 x)  40mM Tris; 1 mM EDTA; 20mM acetic acid; pH 8,0 
 
3.1.5.2 Protein biochemical methods 
SDS-PAGE and Westernblot 
10 x PBS 140mM NaCl; 3mM KCl; 10mM Na2HPO4; 1,5mM 
KH2PO4; pH 7,4  
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4 x loading buffer 500mM Tris; 4% SDS; 20-30% glycerol; 40mM DTT; 
bromophenol blue; pH 6,8 
APS 10 %    1g APS to 10ml ddH2O 
Blocking solution   1 x PBS; 0,1% Tween 20; 5% skimmed milk powder 
10% BSA    2g BSA in 20ml 1xPBS  
Resolving gel 10% 375mM Tris/HCl (pH 8,8); 5% acrylamid mix (37,5:1); 
0,1% SDS; 0,1% APS; 0,01% TEMED 
1 x running buffer   25mM Tris; 191mM glycine; 0,35mM SDS 
SDS 10 %    1g SDS to 10ml ddH2O 
Stacking gel  125mM Tris/HCl (pH 6,8); 5% acrylamid mix (37,5:1);  
0,1% SDS; 0,1% APS; 0,01% TEMED 
Stripping buffer 62,5mM Tris; 69,3mM SDS; pH: 6,8 
1 x transfer buffer 250mM Tris; 192mM glycine; 20% methanol; pH 8,3 
Washing buffer   1 x PBS; 0,1% Tween 20 
 
3.1.6 Enzymes 
AMV Reverse Transcriptase      Fermentas (St. Leon-Rot) 
RNasin® Plus RNase inhibitor     Promega (Mannheim) 
T4 DNA-Ligase       Fermentas (St. Leon-Rot) 
3.1.6.1 Restriction enzymes  
The used restriction enzymes BamHI, BglII, HindIII, KpnI, NcoI, NotI, SacII, XbaI, derive from 
the companies Fermentas (St. Leon-Rot). 
3.1.7 Antibodies 
3.1.7.1 Protein biochemical methods 
Primary 
target prot. source clonality protein size description supplier 
LNK goat polyclonal 68 kDa sc-19743 Santa Cruz, 
Biotechnology 
GAPDH mouse monoclonal 37 kDa sc-32233 Santa Cruz, 
Biotechnology 
The LNK antibody was used in dilution of 1:100 or 1:200 in 2%(w/v) BSA. The GAPDH 
antibody was used 1:2000 or 1:4000 in 1 x PBS; 0,1 %(v/v) Tween 20; 5 %(w/v) skimmed 
milk powder. 
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Secondary 
Anti goat  Donkey IgG  1:5000  sc-2020 Santa Cruz 
Anti mouse  Goat IgG  1:5000  sc-2005 Santa Cruz 
All secondary antibodies were conjugated with horseradish peroxidase and were obtained 
from Santa Cruz Biotechnology. They have been solubilized in 1 x PBS; 0,1 %(v/v) Tween 
20; 5 %(w/v) skimmed milk powder. 
 
3.1.7.2 Flow cytometry 
target protein clone manufacturer fluorochrome 
Gr.-1 RB6-8C5 BioLegend APC 
CD11b M1/70 BioLegend PE 
B220 RA3-6B2 BioLegend PE 
B220 RA3-6B2 BioLegend APC-Cy7 
CD3e 145-2C11 BioLegend APC 
Ter119 Ter-119 BioLegend PE 
ckit 2B8 BioLegend APC 
mCD45 RA3-6B2 BioLegend PE 
hCD45 HI30 BioLegend APC 
Sca1 D7 BioLegend Pe-Cy7 
3.1.8 Oligonucleotides for RT-PCR 
gene description sequence qPCR 
conditions 
Annealing 
temperature 
fragment 
length 
IgLL11 CS1580 
CS1581 
TTGGTATGTCTTTGGTGGTGGGAC 
TAAGGAAGGCAGGAACAGAGTGAC 
64°C, 6sec 250bp 
mHPRT MKF35 
MKF36 
GCTGGTGAAAAGGACCTCT 
CACAGGACTAGAACACCTGC 
62°C, 10sec 250bp 
Rag1 CS849 
CS850 
ATGCTGATGGGAAGTCAAGC 
AATCCTGGCAATGAGGTCTG 
60°C, 10sec 200bp 
 
 
 
                                                
1 Lukin et al., PNAS 2010 
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3.1.9 Plasmids 
Helper plasmid for virus production 
R690   pSV40-gag/pol; carries the MoMLV gag- and pol-genes under the control of 
   the SV40 promoter (Beyer et al., 2002) 
#583   pCMVgagpol/RRE, lentiviral gag/pol/RRE expression vector (Dull et al., 
1998) 
#584   pRSV-REV, lentiviral REV expression vector (Dull et al., 1998) 
#522   pEcoenv-I-puro; carries the ecotropical ecotropic Env-gene under the 
control of the EF1α promoter (Morita et al., 2000) 
R861   pVSV-GNJ (Beyer et al., 2002) 
R916   pFeline endogenous virus (RD114) env (Cosset et al., 1995) 
 
γ-Retroviral constructs 
R1331 pRMys-iV, γ-retroviral vector with venus as reporter gene (Kitamura et 
al., 2003) 
R1481  pRMys-IKZFv6-ERt2-iV, γ-retroviral vector with venus as reporter gene, 
containing among others the dominant negative isoform 6 of IKZF as 
well as the inducible estrogen receptor ERt2 
R1496 pRMys-hCRLF2*-iV, γ-retroviral vector with venus as reporter gene, 
containing among others the mutant form of human CRLF2 
R1515 pRMys-strep-ERt2-iV, γ-retroviral vector with venus as reporter gene, 
containing among others the inducible estrogen receptor Ert2 
R1518 pRMys-hCRLF2*-iCer, γ-retroviral vector with cerulean as reporter 
gene, containing among others the mutant form of human CRLF2 
R1558 pRMys-iBFP-2a-puro+, γ-retroviral vector with BFP as reporter gene 
R1566 pRMys-Ikzf1Δ6-iBFP-2a-puro+, γ-retroviral vector with BFP as reporter 
gene, containing among others the dominant negative isoform 6 of 
IKZF 
 
Lentiviral constructs/ LeGO vectors (Weber et al., 2008) 
#834  pLeGO-iG2/Puro+, Lentiviral vector with eGFP as reporter gene, 
containing among other a puromycin resistance gene 
R1346   piCer2, Lentiviral vector with Cerulean as reporter gene 
R1505  LeGO-iG2-Puro+CTAP-mJak2.9b, Lentiviral vector with eGFP as 
reporter gene, containing among others the R683G mutated form of 
murine Jak2 as well as puromycin as resistance gene 
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R1507  LeGO-hLNKwt-iCer2, Lentiviral vector with cerulean as reporter gene, 
containing among others the human LNK (wt) 
R1520  LeGO-hCRLF2*-iCer2, Lentiviral vector with cerulean as reporter gene, 
containing among others the mutated form of human CRLF2 
R1541  LeGO-PI3KCA-H1072R-iB2-Puro+, Lentiviral vector with BFP as 
reporter gene, containing among others a puromycin resistance gene 
R1542  LeGO-hLNK-iB2-Puro+, Lentiviral vector with BFP as reporter gene, 
containing among others the human LNK (wt) as well as puromycin as 
resistance gene 
R1543  LeGO-iB2-Puro+, Lentiviral vector with BFP as reporter gene, 
containing a puromycin resistance gene 
3.1.10 Bacteria strains 
The bacteria strain Escherichia coli XL10-GOLD® (Stratagene, La Jolla, USA) was used for 
all experiments of this thesis. 
3.1.11 Mouse strains 
All mouse strains were maintained under specific pathogen-free conditions at the animal 
facility of the Heinrich-Pette-Institute. 
C57BL/6 Ly5.2 mice were used for isolation of bone marrow cells, which were transplanted 
into C57BL/6 Ly5.1 mice. These two mice strains are genetically identical, apart from the 
Ptprc gene (= congenic). 
Lnk-/- or Lnk+/+ 129 mouse strains were used for the isolation of bone marrow cells, which 
were transplanted into Lnk+/+ 129 mice.  
NOD/SCID/γcnull mice (Ito et al., 2002) were used for xenotransplantation of the infected 
CD34+ cells. This mouse strain represents immunodeficient mice and therefore they were 
kept in sterile isolator cages and were fed with autoclaved food and water only. Their 
treatment only took place under sterile conditions. 
3.1.12 Cell lines 
Ba/F3 cells 
Ba/F3 cells are murine bone marrow-derived pro-B-cells, which normally grow IL-3 
dependent (Palacios and Steinmetz, 1985). They are suspension cells and were cultured in 
RPMI medium with 10%(v/v) FCS (Biochrom) and 5%(v/v) BPV-mIL3, produced by a 
myeloma cell line (Karasuyama and Melchers, 1988). 
The cells were passaged every 2-3 days in a ratio of 1:5 or 1:10. Two different Ba/F3 cell 
lines were used: 
1. Ba/F3 IL-3-dependent 
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2. Ba/F3 R1496 (containing CRLF2* vector) IL-3 independent 
 
Bmi-Flt3 cells 
Bmi-Flt3 cells represent murine, bone marrow derived lymphoblasts from FLT3-induced ALL, 
which possess a constitutive expression of the Flt3 receptor. These cells were cultured in α-
MEM medium with 10%(v/v)FCS (Biochrom) . 
 
HEK293T cells 
293T cells belong to the HEK cells and represent „Human embryonic kidney cells“. This cell 
lineage (ATCC #CRL-11268) is a transformation product of human embryonic kidney cells 
with parts of the DNA of the human adenovirus. 293T cells are adherent growing cells, which 
express the SV40 large antigen and therefore allow the replication of plasmids with SV40 
origin of replication. They were used for virus production. 
293T cells were cultured at a confluency of 70% with DMEM medium with 10%(v/v)FBS 
(Lonza). The cells were passaged every 2-3 days in a 1:5 or 1:10 ratio.  
 
SC-1 cells 
SC-1 cells present a cell lineage, which is derived from fetal mouse fibroblasts (ATCC #CRL-
1404). They were cultured in DMEM with 10% FCS (Biochrom). 
 
CD34 cells 
CD34 cells were isolated from human cord blood by Ficoll gradient. These cells represent 
early progenitor and stem cells. They were cultured in SFEM medium (1%(v/v) P/S, 1%(v/v) 
glutamine, 1%(v/v) sodium pyruvate) and the cytokines rhFlt3(100ng/ml), rhSCF(100ng/ml), 
rhTPO(20ng/ml) and rhIL-6(20ng/ml). 
3.2 Methods 
3.2.1 Cell culture methods 
3.2.1.1 Cultivation of different suspension cells over time 
Suspension cells were cultivated in non-tissue-culture 6-well plates at 37°C and 5% CO2. 
Depending on the cell density, the cells were passaged every 2-3 days at a ratio of 1:2 – 
1:10, depending on the cell type. 
3.2.1.2 Freezing of cells 
The freezing medium consisted of 90%FCS plus 10%DMSO and has to be kept on ice all the 
time. 
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Cells were centrifuged for 5min, 1000rpm at 21°C. After centrifugation the supernatant was 
discarded. The cell pellet was then resuspended in the cold freezing medium (up to 5x106 
cells per ml medium). The cells were transferred into a cryotube. The vials were put in a 
freezing container (4°C) and were cooled down slowly in the -80°C freezer. The cells were 
stored in -190°C nitrogen after 24 hours. 
3.2.1.3 Thawing of cells 
The tubes containing the frozen cells were thawed in the 37°C water bath and were then 
taken up with a pasteur pipette and added drop wise to an adequate amount of 
corresponding medium to dilute the DMSO. The cells were then centrifuged 5min, 1000rpm 
at 21°C. The cell pellet was resuspended in 3ml of the corresponding medium and the cells 
were transferred into the well and cultivated at 37°C with 5%CO2. 
3.2.1.4 Transfection of 293T cells- production of infectious virus particles 
On day one 293T cells had to be seeded in the afternoon at a density of 4x106 cells per 9cm 
tissue culture dish in 10ml of the corresponding cell culture medium. On day two the cells 
were transfected, via the calcium phosphate method, with the viral constructs and the helper 
plasmids, encoding for gag, pol and env. Therefore, the plasmids were diluted in nuclease 
free water and 62,5µl 2M CaCl2 solution per approach was added like the following: 
 
Lentivirus: -­‐ Vector plasmid   10µg/dish -­‐ Gag/Pol plasmid:   10µg/dish -­‐ Rev plasmid:    5µg/dish -­‐ Envelope plasmid:   2µg/dish phCMV-VSV-G 
           4µg/dish ecotropic Env -­‐ CaCl2:    62,5µl/dish -­‐ Nuclease free water:  ad 500µl 
 
γ-Retrovirus: -­‐ Vector plasmid   5µg/dish -­‐ Gag/Pol plasmid:   10µg/dish -­‐ Envelope plasmid:   3µg/dish ecotropic Env -­‐ CaCl2:    62,5µl/dish -­‐ Nuclease free water:  ad 500µl 
After diluting the plasmids, the DNA/CaCl2 mix was added drop wise to 500µl of HEPES 
buffer (2x), while producing air bubbles with the help of a pasteur pipette in the buffer. This 
solution was incubated for 20min at room temperature. The old medium was aspirated from 
  39 
 39 
the 293T cells. 10ml of fresh medium were added to the cells as well as 25µM chloroquine 
per plate. The DNA mix was added drop wise to the cells, the plates were swirled gently and 
then incubated for 6 -12 hours at 37°C and 5%CO2. 
After the incubation time, the medium was changed to 8ml without chloroquine. Starting 12 
hours later, the supernatant containing the virus particles was harvested every 12 hours. The 
harvest began on day three in the morning by taking up the whole supernatant with a syringe 
and by filtrating it through a 0,22µm Millex-GP sterile filter into 15ml tubes. Then 6ml of fresh 
medium were added to the cells and the viral supernatants were frozen at -70°C. This was 
repeated every 12 hours for 72 hours. 
3.2.1.5 Titer determination of produced viruses via FACS analysis 
On day one 5x104 293T cells or SC-1 cells, depending on the envelope protein of the virus, 
were seeded in 500µl medium per well in a 24-well plate. Polybrene was added to every well 
at a final concentration of 8µg/ml. The thawed viral supernatants were added to the cells in 
duplets, once 20µl and once 100µl. The plate was centrifuged one hour, 2000rpm at 24°C 
and was the incubated at 37°C overnight. On day two the medium was removed and 1ml of 
fresh medium was added per well. 
On day four the medium was removed, the cells were detached with trypsin/EDTA, 
centrifuged for 5 min at 2000rpm and resolved in 1xPBS. The cells were examined via FACS 
analysis and the virus titer was calculated with the following formula: 
 
Titer (gtu/ml) = number of seeded cells x proportion of transduced cells / volume of added 
supernatant 
 
3.2.1.6 Infection of target cells  
Infection via retronectin 
To transfect the cells via retronectin, a 6 well plate was coated with 2ml retronectin (48µg/ml) 
and incubated for 2 hours at RT. Then the retronectin solution was discarded and stopping 
solution (PBS/2%(w/v) BSA) was added to the well and incubated for 30min at RT. The BSA 
solution was abolished and HBSS/2,5%(v/v) 1M Hepes was added to the well for 
neutralization, which was removed shortly before the virus application. Therefore, the 
HBSS/2,5%(v/v) 1M Hepes solution was discarded from the wells and 1,5ml of the virus 
supernatant (with ecotropic Env or fel env as envelope protein) was applied per well. 
Afterwards, the plate was centrifuged for 20min, 2000rpm at 4°C. After centrifugation 1ml of 
supernatant was discarded of each well and 1ml of fresh virus was added to each well and 
centrifugation of the plate was performed as before. This whole step was then repeated 
twice. After the fourth centrifugation the last virus supernatant was removed just before the 
addition of the cells. Finally, the target cells were transferred to the virus-coated wells and 
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incubated overnight at 37°C and 5%CO2. On day two a new 6 well plate was coated with 
virus as the day before and after virus coating the cells, which were infected the day before, 
were transferred to the newly coated wells. The detachment of the cells was performed with 
the help of a spatula. On the following days the transduced cells could either be sorted and 
cultivated or transplanted into mice. 
 
Infection via spinoculation and following cell sorting 
2x105 cells were transferred to a new well of a 6-well plate. 1ml of the thawed virus 
supernatant was added directly to the cells as well as medium up to 3ml per well and 
polybrene at a concentration of 8µg/ml. The plate was centrifuged 1h, 2000rpm at room 
temperature. The transduction was repeated identically the next day. After the second 
infection the cells were cultivated for several days. The infected cells were sorted after 4-5 
days using the flow cytometer.  
To sort a specific cell population out of a mixed cell population the whole content of the well 
was centrifuged 5min, 1000rpm at 21°C. The supernatant was discarded and the pellet was 
resuspended in 1xPBS. The sorting was then performed via FACS. The cells were sorted 
into FACS tubes containing the corresponding medium as well as a broad-spectrum 
antibiotic, as for example Ciprobay, at a concentration of 1:125. After the sorting process the 
cells were centrifuged for 5min, 1000rpm at 21°C. The supernatant was discarded and the 
pellet was resuspended in the corresponding medium. The cell solution was then transferred 
into a well of a 12-well plate and Ciprobay was added at a concentration of 1:40. The sorted 
cells were cultured with the addition of Ciprobay for at least one week. 
3.2.1.6 Puromycin selection 
Several of the vectors, which were used in this study, contained a puromycin resistance 
gene. If the transduction rates were too low cells, which express this vector, could be 
enriched by puromycin selection. 
The selection was performed by adding 1µg/ml of puromycin (stock 1µg/µl) to the cells, 
which were infected twice. Fresh puromycin was added to the cells every two days at a 
concentration of 1µg/ml. The infection rate of these cells was analyzed via flow cytometry 
four days after the puromycin selection. The preparation for the analysis was accomplished 
as before.  
3.2.1.7 Competitions assay of Ba/F3 cells 
To analyze the proliferation behavior of differently infected Ba/F3 cells a competitions assay 
can be performed in vitro. The cells, which have been infected with the target vector and 
have been puromycin-selected, were counted and the percentage of vector containing cells 
(=BFP positive cells) was analyzed via flow cytometer. Afterwards these cells were mixed 
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with uninfected cells of the same cell line. The target was to seed 5x105 cells at the ratio of 
70% infected cells to 30% of uninfected cells per well of a 12-well plate. The cells were 
mixed and then the cell ratio was confirmed on the flow cytometer (day 0). The change of the 
ratio of infected to uninfected cells was then analyzed every two to three days via flow 
cytometer using an aliquot of the cell suspension. Furthermore, the cells were passaged 1:5 
every two days. 
3.2.2 Mouse experiments 
3.2.2.1 Enrichment of human and murine primary cells 
Primary cells of murine bone marrow and human cord blood were cultured as mentioned 
above in non-tissue-culture plates. 
3.2.2.1.1 Isolation of murine bone marrow  
The previously narcotized animals were sacrificed via cervical dislocation. The bone marrow 
was isolated from the murine tibia and femur. The whole isolation was performed at the 
sterile bench with a 1ml syringe and cannula. The bones were cut at one end and by 
perforating the other end the bone marrow was flushed into a falcon tube, containing IMDM 
medium with 5%FCS, 1%Pen/Strep and 2mM glutamine. The cells were washed once with 
IMDM. After washing, the cell pellet was resuspended in an adequate volume of lysis buffer, 
so that the erythrocytes would burst due to the osmotic pressure. After centrifugation of 5min 
at 1200rpm, the cell pellet was resuspended in murine SFEM medium (4mM glutamine; 1mM 
sodium pyruvate; 1%(v/v) Penicillin/streptomycin) containing the corresponding cytokines 
(1:1000) (5x105-1x106 cells per ml). 
3.2.2.1.2 Lineage depletion of murine bone marrow cells 
Stem cells as well as early progenitor cells represent the target cells for infection and 
subsequent analysis and transplantation. For this purpose they have to be isolated and 
enriched out of the whole murine bone marrow or human cord blood. There are two different 
ways, which were performed during this thesis. 
 
Lineage depletion by 5-FU 
One way of lineage depletion is 5-FU treatment. 5-FU acts toxically against strongly 
proliferating cells and therefore leads to the enrichment of early progenitor cells and HSCs in 
the haematopoietic system. Due to experienced data it is known that the isolation of bone 
marrow cells three days after 5-FU treatment leads to the enrichment of myeloid progenitors. 
Enrichment of B-cell progenitors needs more time. Consequently, our data indicates that the 
isolation of bone marrow five days after 5-FU treatment resulted in a population with lots of 
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B-cell progenitors. The mice were treated with 150µg 5-FU per g body weight in a volume of 
10µl 1xPBS per g body weight via intraperitoneal injection.  
 
Lineage depletion by MACS columns 
Another form to isolate the HSCs and early progenitors out of the bone marrow is the 
depletion of lineage+ cells with MACS column. For this purpose the cells were counted after 
the bone marrow isolation and then centrifuged for 10min, 1200rpm at room temperature. 
The pellet was resuspended in 400µl of PBS/0,5%FCS per 1x108 cells and mixed. 
Thereupon 100µl per 1x108 cells of Biotin-antibody cocktail was applied to the cells to stain 
the lineage positive cells. The cells were mixed and incubated on ice for 10min. To dilute 
unbound antibodies, 300µl per 1x108 cells of cold PBS/0,5%(v/v) FCS were added to the 
cells as well as 200µl per 1x108 cells of anti-biotin microbeads (secondary antibody) so that 
the magnetically labeled cells are held in suspension within the column. The cells were 
mixed again and then incubated for 15min on ice. After that the cells were washed twice with 
IMDM/5%FCS medium, were centrifuged for 5min and 1200rpm. The cell pellet was 
resuspended in IMDM medium/5%FCS (2ml per 1x108 cells). 
Then the LD column within the magnet had to be equilibrated with IMDM (5%FCS, 1%P/S, 
1% glutamine) via the 30µm filter on top of the column. The tubes with this flow-through were 
abolished and new 15ml tubes were positioned under the columns. 2ml of the labeled cell 
suspension were applied to the column via the filter. Each column was washed twice by 
applying 1ml of medium to the column. The flow-through consisted of the lineage negative, 
unlabeled fraction of the bone marrow cells. The tubes were then centrifuged for 5min and 
1000rpm. The pellet was resuspended in 3ml of SFEM medium (1%(v/v) P/S, 2mM 
glutamine, 1mM sodium pyruvate, rmSCF (100ng/ml), rhFlt3 (100ng/ml), rhIL-11 (100ng/ml) 
and rmIL-3 (10ng/ml)). The cells were transferred to one 6-well and Ciprobay (1:125) was 
added.  
3.2.2.2 Infection of the murine bone marrow cells 
To guarantee an efficient infection with the virus, infection via retronectin was performed as 
described above. The cells were infected on day one and two after bone marrow isolation. 
On day four an aliquot of the cells was taken to analyze the infection rate of the cells, 
whereas the rest of the cells was transplanted, as described in 3.2.2.5. 
3.2.2.3 Infection of the CD34+ cells 
The cells were thawed 24 hours before the first infection. 1,8x106 cells were cultured per well 
of a 6-well plate in 3ml of SFEM medium (1%(v/v) P/S, 2mM glutamine, 1mM sodium 
pyruvate) with the corresponding cytokines. The infection with the virus was performed twice 
via a combination of retronectin-depending (fel env) infection and spinoculation (VSV-G). 
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3.2.2.4 Colony formation assay of infected bone marrow cells 
A methylcellulose assay was used to analyze the proliferation behavior and growth 
advantage of differently infected and non-infected bone marrow cells. This semisolid medium 
was used due to the fact that haematopoietic progenitors are able to proliferate and form 
colonies in this medium as a response to cytokine stimulation. Per approach 3,3ml of mouse 
methylcellulose (M3231) were thawed. Then 5x104-2x105 cells/ml were added to the 
methylcellulose as wells as Pen/Strep (33U), 1:1000 of rmIL7 (20ng/ml) and if necessary 
IMDM up to a volume of 330µl. An aliquot of the original cells was used for FACS analysis on 
day zero. After mixing gently to avoid air bubble formation, the methylcellulose approach was 
performed in triplets on 35mm plates. The colony assays were incubated at 37°C and 
5%CO2. After one week the colonies/cells were analyzed. For this purpose colonies were 
counted via microscopy and one plate of each approach was analyzed via FACS. The 
methylcellulose containing the cells was detached by adding 1xPBS to the plates, 
resuspending, pooling the cells and washing the plates. Then the cells were centrifuged 
5min, 1200rpm and the pellet was resuspended in 1xPBS. The cells were then analyzed via 
flow cytometry directly or they were first stained and then analyzed. The remaining colonies 
were replated again by seeding the same cell density after detachment, washing, and 
counting of the cells into new methylcellulose. FACS analysis as well as replating was 
performed again at day 13. The final analysis of the cells without replating was performed 
four weeks after the experimental start. 
3.2.2.5 Allotransplantation 
If the bone marrow cells should be transplanted, they were counted on day three after the 
bone marrow isolation to estimate the cell number and consequently the number of mice that 
were going to be transplanted. The recipient mice (129 or C57BL/6J Ly5.1) were irradiated 
lethally with a dose of 9 Gray (=25min for C57BL/6J Ly5.1 mice) or 7,6 Gray (=21min for 129 
mice) of γ-rays. The prepared, infected cells together with fresh spleen support cells were i.v. 
-injected at the earliest 2 hours after irradiation and not later than 24 hours after irradiation. 
About 1x106 cells were transplanted per mouse. After transplantation the mice were treated 
with Baytril ® 2,5% at a concentration of 400µl/100ml drinking water for three weeks. 
Induction via tamoxifen was initiated seven weeks post transplantation. 
Due to lethal irradiation the mice loose the bigger part of haematopoietic cells and therefore 
need haematopoietic support cells, mainly erythrocytes, to stay alive until the transplanted 
early progenitor cells engraft and produce new cells. The spleen of a syngeneic mouse was 
isolated, because this organ possesses percentaged only a few stem cells but many 
erythrocytes. The spleen cells were transferred into a small tissue culture plate. IMDM 
(5%(v/v) FCS; 1%(v/v) P/S; 1%(v/v) glutamine) was added to the spleen, which was crushed 
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with the backside of a syringe. The solution was collected with a 20ml syringe and 
transferred through a FACS filter into a sterile FACS tube to count the cells. 3x104 splenic 
support cells were mixed with the prepared, infected cells and the mixture was transplanted. 
3.2.2.6 Xenotransplantation 
Infected human CD34+ cells, as described in 3.2.2.3, were transplanted into immunodeficient 
NOD/SCID/γcnull mice that show a functional incompetence of B-, T- and NK-cells to avoid a 
rejection of the human cells. The irradiation and transplantation of the NOD/SCID/γcnull 
recipient mice was performed as described for the allotransplantation, but just with a dose of 
1,6 Gray(=4,5min).  
3.2.2.7 Analysis of sick animals 
If an animal showed serious disease symptoms according to the guidelines on the care and 
use of animals for scientific purposes, they were sacrificed and analyzed. 
 
Analysis of the organs 
Peripheral blood was taken and analyzed via Hemavet and FACS analysis. 
After taking blood, the organs of the sacrificed animal were analyzed. For this purpose the 
spleen was weighted, parts of the spleen and liver were fixed in formaldehyde. The fixation of 
the sternum was performed in CALfix. The splenic cells and bone marrow cells were also 
analyzed via FACS. 
 
Preparation of spleen, peripheral blood and bone marrow for analysis via flow cytometry 
The spleen was processed to a single cell suspension by pressing the spleen through a 
160µm filter into 1xPBS. The isolation of the bone marrow was performed as it was 
described for the gain of primary cells and was resuspended in 1xPBS. The spleen and 
blood were erylysed by adding 1xlyse buffer and after centrifugation the cells were 
resuspended in 1xPBS. Afterwards the cells could be analyzed directly via flow cytometry or 
they could be stained for 20min at 4°C with antibodies (amount according to manufacturer 
instruction) that are coupled to different fluorochromes. After staining, the cells were washed 
once with 1xPBS and after centrifugation, they were resuspended in 1xPBS and were then 
analyzed via flow cytometry. 
3.2.3 Molecular methods 
3.2.3.1 Standard methods 
Agarose gel electrophoresis, ethanol precipitation, phenol/chloroform extraction and heat 
shock transformation were performed according to standard protocols. The isolation and 
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purification of plasmid DNA out of bacteria culture and agarose gels were performed with the 
help of the mentioned kits (3.1.3) and according to manufacturer’s instructions. 
3.2.3.2 Protein biochemical methods 
Whole cell lysate and protein extraction 
To perform cells lysis and isolate the proteins out of the cells, 1x107 cells were first washed 
with cold 1xPBS. The cells were centrifuged for 5min, 1000rpm at 4°C and put on ice 
afterwards. The supernatant was discarded and the cells were resuspended in 200µl of cold 
lysis buffer II (50mM Tris(pH=7,4), 100mM NaCl, 10% glycerol, 0,1%Triton X-100, 1mM DTT, 
1mM EDTA). The cells were then incubated on ice for 0,5 to one hour, while vortexing the 
cells every 10min. Additionally, a sonificator was used for 30 sec to finally break open the 
cells. To remove the cell debris the samples were finally centrifuged for 10min, 13000rpm at 
4°C and the supernatant was transferred into an Eppendorf tube. The protein concentration 
was measured via Nanodrop. The protein extracts were stored at -80°C. 
 
SDS-PAGE and Western blot  
To analyze the proteins, which were gained from the whole cell lysates, electrophoretic 
separation via SDS-PAGE was performed. The proteins were first denaturated by exposing 
the samples for 5min to 95°C. Afterwards the samples were centrifuged 1min, 12.000rpm at 
room temperature. 20-80µg of the supernatant of each protein sample were applied to a 10% 
SDS gel (3.1.5.2) to separate the proteins according to their molecular weight. The stacking 
gel was run at 80V and the separation gel at 120V. The membrane was activated for 1min in 
100% methanol at room temperature. Afterwards it was transferred into dH2O for 2min. The 
membrane was then incubated for 5min in 1x Towbin transfer buffer (350mM Tris, 192mM 
glycine, 20% methanol, pH 8,3). To visualize the target proteins with the help of specific 
antibodies the transfer of the proteins from the gel to the membrane was performed via 
tankblot at 100V with ice cooling for 1 hour. After blotting, the membrane was incubated in 
blocking solution (5% skimmed milk powder; 0,1% Tween 20 in PBS) for one hour at room 
temperature to prevent unspecific binding of the antibodies to the membrane. Then the 
membrane was incubated with the first antibody at the corresponding concentration (3.1.7.1) 
overnight at 4°C. On the following day the membrane was washed three times for 10min with 
washing buffer (1xPBS; 0,1%Tween 20) to remove unbound antibodies. After washing, the 
membrane was incubated with the peroxidase associated secondary antibody (3.1.7.1) while 
being shaken. After two hours, washing was performed as before three times to remove 
unbound secondary antibody.  
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ECL reaction 
The Amershan ECL-Detection™plus kit (GE-Healthcare, Munich) was used according to 
manufacturer’s instructions to visualize the proteins. For this purpose 200µl of the ECL-
solution were added to the protein side of the membrane. Then the X-ray film was applied to 
the membrane and was developed after several seconds up to half an hour, depending on 
the antibody. The blackening of the film on the side where the secondary antibody has bound 
happens due to the fact that the HRP catalyzes the reaction H2O2 with luminole to an oxide of 
luminole, which leads to a chemiluminescence reaction. 
For further use of the membrane, it could be washed again three times with washing buffer 
and then be blocked again for one hour with blocking solution and then the primary antibody 
could be applied again. To completely remove all antibodies, the membrane could be 
washed three times and then incubated in 50ml of ECL stripping buffer, (350µl β-
mercaptoethanol added) for 15min at 50°C. After that the membrane should be washed 
several times with washing buffer and could then be blocked and incubated with the primary 
antibody again. 
3.2.3.3 Nucleic acid analytical methods 
DNA isolation (Maxi-, midi-, miniprep) 
The DNA isolation out of bacteria culture was performed by using the Maxi-, Midi- and 
Miniprep Kit (Qiagen) and were performed according to manufacturer’s instructions. The 
resulting DNA concentration was measured using the Nanodrop. To test whether the isolated 
DNA correlated with the target DNA a test restriction was performed.  
The restriction approach was incubated at 37°C for 1 hour. After that, the restriction was 
applied to a 1% agarose gel und the resulting bands were compared with the expected ones.  
 
RNA isolation 
1-2x106 cells were used for RNA isolation and the RNA was isolated according to the 
protocol of the RNeasy Mini Kit of Qiagen (Hilden). The RNA was diluted in 25µl of RNase-
free water. Then the RNA concentration was determined via Nanodrop. 
 
cDNA synthesis 
The previously isolated RNA was used for cDNA synthesis. The AMV Reverse Transcriptase 
(Fermentas, ST. Leon-Rot) was used for reverse transcription. Additionally, random primer 
(Roche, Mannheim) were used, so that the whole mRNA could be transcribed into cDNA. 
About 1µg of RNA template was used per reaction and each reaction contained the 
following: 1µg RNA, 5x AMV buffer (Fermentas, St. Leon-Rot), 1mM dNTP’s (Qiagen, 
Hilden), 1µl random primer, 40U rRnasin Plus® RNase inhibitor (Promega , Mannheim) and 
10U AMV reverse transcriptase. If needed, the end volume of 20µl was filled up with H2O. 
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The reaction was performed by incubating the samples for 10min at 25°C and then for 60min 
at 50°C to heat-inactivate the enzymes.  
 
Quantitative Real-time PCR 
The Light Cycler® FastStart DNA Master SYBR Green 1 kit of Roche was used for 
quantitative Real-time PCR. With the help of this method it is possible to quantify the amount 
of transcripts of different genes in a cDNA sample. Here the fluorescence marker SYBR 
Green I interacts with double stranded DNA, whereas the fluorescence signal increases with 
the amount of DNA. 0,5µl of cDNA was used per 20µl approach as well as 5pmol of the 
forward and reverse primer. The same PCR program was chosen for all qRT-PCRs, whereas 
elongation time and annealing temperature varied due to the different primer properties 
(3.1.8). The PCR cycle consisted of an initial heating step for 10min at 95°C, followed by a 
cycle of denaturation (10sec, 95°C), the annealing (10sec, x°C) and then the elongation (x 
sec, 72°C). This cycle was repeated 40 times. 
The analysis of the quantitative Real-time PCR was performed using the ΔΔCt-method, 
which was established by Pfaffl (Pfaffl, 2001). The measurement of the transcription of the 
HPRT gene, as reference gene, was used in all cDNA samples for normalization. The mRNA 
expression in control cells was set as 1 and consequently the mRNA expression of the target 
cells was calculated compared to the control cells. 
To check the PCR product, a melting point analysis was performed after each PCR reaction. 
For this purpose the temperature in the reaction capillary was increased slowly so that the 
double stranded DNA denaturates at a melting point, which is specific for the PCR product. 
This leads to the release of the whole fluorescence marker and a significant decrease in 
fluorescence. The resulting melting curve should be comparable in all cDNA samples. 
The PCR conditions for the different primer pairs are listed in 3.1.8. Positive controls as well 
as water control were used for the primer pairs. 
After real-time PCR all PCR products were checked on a 1,5% agarose gel to see whether 
there is only one PCR product with the right size. 
 
Cloning of the LNK vector  
The existing vector LeGO-Puro+ was cleaved with NotI. The whole restriction approach was 
applied to a 0,8% agarose gel. The upper band, which presented the cleaved vector, was cut 
out of the gel. The gel fragment was applied to a column and by centrifugation for 5min, 
5000rpm at room temperature the DNA was eluted from the gel. The DNA in the flow-through 
was religated. After religation, X10Gold were transformed via heat shock procedure. A 
miniprep of each of the overnight cultures of ten clones was performed and a test restriction 
of the isolated DNA was performed as usual with XbaI and BamHI. After the testrestriction, 
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the approach was zipped to prevent religation of the vector. The restricted and zipped 
plasmid DNA was applied to a 1% agarose gel. The resulting band of a positive clone was 
cut out of the gel and a gel elution was performed as before. A phenol-chloroform 
precipitation of the restricted and zipped vector was performed afterwards.  
The existing vector R1507 (human, wt LNK) was cleaved with BamHI. The restriction 
approach was applied to a 1% agarose gel. The lower of the two bands, the LNK fragment, 
was cut out of the gel and the DNA was eluted according to manufacturer’s instructions. 
The ligation of the LNK fragment into the LeGO-iB2 vector was performed according to 
manufacturer’s instructions with 5U T4 DNA ligase, 16µl LeGO-iB2 vector and 10µl LNK 
fragment. After transformation, the existing colonies were checked for the right orientation of 
the LNK fragment by cleaving the gained DNA with convenient restriction enzymes (NotI, 
BamHI, HindIII). 
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4 Results 
4.1 Modeling B-ALL 
4.1.1 Modeling B-ALL in the human system with Jak2* plus IKZFΔ6-ERt2 
It is known that the mutation of the tyrosine kinase JAK2, together with aberrantly expressed 
transcription factors, like IKAROS, is often found in diseases such as high-risk B-ALL. 
Consequently, we wanted to optimize a mouse model system to analyze the effect of Jak2 
mutation occurring together with the dominant negative mutant IKAROS (IKZFΔ6) on normal 
haematopoiesis in vivo, using human CD34+ cells, which after transduction would be 
transplanted into immune-deficient mice and monitored for clinical symptoms of disease. 
Retroviral vectors were used to introduce the JAK2-R682G mutant and an inducible IKZFΔ6-
ERt2 fusion protein, in which IKZFΔ6 is fused to a tamoxifen-inducible estrogen receptor. In 
the absence of tamoxifen, the IKZFΔ6 mutant remains in the cytoplasm, and only moves to 
the nucleus to inhibit Ikzf1 function when tamoxifen binds to the ERt2 component. An 
inducible approach was used because it was not clear, whether lymphoid development would 
be completely blocked if the dominant-negative form of IKAROS was expressed in HSC. 
Previous experiments in our lab had shown that retroviral-transduced human CD34+ cells, 
which represent pluripotent HSC, do not have or have lost long-term engraftment capacity in 
immunodeficient NSG mice. This is probably due to the fact the culture conditions used to 
efficiently infect/transduce human CD34+ cells promoted their differentiation at expense of 
their self-renewal capacity. Alternatively, long-term repopulating cells may have not been 
infected, as they make up a small percentage of CD34+ cells. Consequently it was the goal 
of this experiment to compare different approaches for cell isolation and to test the efficiency 
of retroviral infection and engraftement in NSG mice. In the first approach, CD34+ cells 
obtained by magnetic separation were subjected to further purification by sorting a CD38+ 
and CD38- population. Whereas in the second approach, CD34+ cells were not purified 
further. The experimental approach is depicted in Figure 13. 
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Figure 13 Modeling B-ALL in the human system with Jak2* and IKZFΔ6-ERt2 
Three different approaches of human CD34+ were infected with the lentiviral Jak2* and the gammaretroviral 
IKZFΔ6-ERt2 vectors. The transduced cells were finally transplanted into NSG mice. 
 
In the first approach 3x107 CD34+ cells were thawed and stained with hCD34 and hCD38 for 
sorting. Consequently, the cells were sorted into two different populations: CD34+/CD38- 
cells, which represent the earlier progenitor population and CD34+/CD38+ cells, which 
represent the later progenitor population. Sorting resulted in 5,5x105 CD34+/CD38+ cells and 
3,2x105 CD34+/CD38- cells, which were infected on day zero and one with a concentrated 
Jak2* (lentiviral vector/VSV-G pseudotyped), concentrated eGFP control (lentiviral 
vector/VSV-G pseudotyped) and IKZFΔ6-ERt2 (gammaretroviral vector/RD114 Env 
pseudotype) vectors. 
In the second approach 1,6x107 CD34+ cells were thawed, not sorted and cultivated 
overnight to avoid stressing the cells. They were infected on day one and two instead of day 
zero with the same pseudotyped vectors.  
Figure 14 visualizes the FACS analysis of the sorted and infected CD34+/CD38+, which 
shows that 27% of the cells were infected with the gammaretroviral IKZFΔ6-ERt2, but they 
did not show lentiviral Jak2* expression at all. The infected CD34+CD38- cells were not 
analyzed via FACS analysis, because due to the low cell number all cells were transplanted. 
The unsorted CD34+ cells showed 60% of IKZFΔ6-ERt2 expression and no Jak2* 
expression again.  
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Figure 14 FACS analysis of the CD34+/CD38+ and unsorted CD34+ cells, which were infected with Jak2* 
plus IKZFΔ6-ERt2 and control vector plus IKZFΔ6-ERt2. 
The CD34+CD38+ cells and unsorted CD34+ cells, which were infected twice, were analyzed via flow cytometry 
using the fluorochromes eGFP for Jak2*/control vector and venus for IKZFΔ6-ERt2. The cells were analyzed right 
before transplantation into NSG mice. 
Looking at the corresponding MOI’s and infection rates, as visualized in Chart 1, it can be 
said that the unsorted cells showed better infection frequencies with IKZFΔ6-ERt2, despite 
lower initial MOI. Three times higher MOI of IKZFΔ6-ERt2 in the sorted cells resulted in about 
half the infection frequency compared to the unsorted approach. The high MOI of the 
lentiviral control vector (30,8) and the following infection frequency of 0% might be the result 
of technical problems and the fact that the titers were tested on mouse fibroblasts.  
In conclusion it can be said that the infection of CD34+ cells with gammaretroviral vectors 
works more efficiently then with lentiviral vectors especially at lower MOIs. 
 
 CD34+CD38+ 
MOI             infection 
CD34+CD38- 
MOI           infection 
unsorted CD34+ 
MOI               infection 
Jak2*+IKZFΔ6-ERt2 
DP 
Jak2* 
IKZFΔ6-ERt2 
 
                            2% 
6,2                       0% 
19,6                   27% 
                  
                        N.D. 
10,6                 N.D. 
33,8                 N.D. 
 
                              0% 
2,1                         0% 
6,4                       60% 
contr.+IKZFΔ6-ERt2 
DP 
control 
IKZFΔ6-ERt2 
 
 
 no infection 
 
                        N.D. 
0,7                   N.D. 
33,8                 N.D. 
 
                              0% 
30,8                       0% 
6,4                       57% 
Chart 1 MOI during infection of the CD34+ cells. 
Three different CD34+ cell populations were infected twice with the IKZFΔ6-ERt2, Jak2* and control vector at 
different MOI’s. This resulted in different infection frequencies. DP stands for “double positive” and indicates the 
percentage of Jak2*/control+IKZFΔ6-ERt2 infected cells. 
The infected cells, which did not proliferate and were low in number, were transplanted into 
immunodeficient NSG mice that were irradiated for 4,5 min (=1,6 Gray) on day three after 
thawing, as shown in Chart 2. 
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Cells no. of 
transplanted 
mice 
no. of transplanted 
cells/mouse 
CD34+CD38-: 
Jak2*+IKZFΔ6-ERt2 
2 4,3x104 
CD34+CD38-: 
control+IKZFΔ6-ERt2 
2 4,3x104 
CD34+CD38+: 
Jak2*+IKZFΔ6-ERt2 
8 6x104 
CD34+CD38+: 
uninfected 
4 3x104 
unsorted CD34+: 
Jak2*+IKZFΔ6-ERt2 
2 1,2x106 
unsorted CD34+: 
control+IKZFΔ6-ERt2 
3 1,3x106 
Chart 2 Transplantation of the different CD34+ cell approaches. 
The different CD34+ cell populations were transplanted into two to 8 mice, transplanting between 4,3x104 and 
1,3x106 cells. The colors indicate the belonging to the respective approach.  
Peripheral blood of these mice was taken and analyzed six weeks post transplantation. The 
blood was stained with hCD45 and mCD45 to determine the percentage of human cells in 
these mice. Furthermore the blood was analyzed to determine the percentage of human cells 
transduced with Jak2* and IKZFΔ6-ERt2 vectors. 
 
 
Figure 15 Analysis of the peripheral blood of the NSG mice six weeks post transplantation. 
The PB of the NSG mice, which were transplanted with Jak2* and IKZFΔ6-ERt2 infected CD34+ cells (sorted and 
not sorted) was stained and analyzed via flow cytometry. The cells were stained for human CD45 as well as for 
mouse CD45 to be able to distinguish between the infected CD34+ cells and the mouse cells. Furthermore the 
cells were checked for the percentage of transduced cells with Jak2* and IKZFΔ6-ERt2, using eGFP and venus 
as fluorochromes. The figure shows the percentages of human cells in the peripheral blood of the mice. PB of the 
mice, which were transplanted with unsorted CD34+ cells, was not analyzed. 
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Looking at Figure 15, it is visible that all mice showed very low percentages of human cells in 
the blood of between 0% and 1,3%. It is known that it is uncommon to see high percentages 
of human cells in the blood after transplantation, but in this experiment the low percentages 
of human cells additionally did not show any transduction with Jak2* and IKZFΔ6-ERt2. As 
consequence it was decided not to start tamoxifen induction. Final analysis of ten of these 
mice was performed five-months post transplantation. The engraftment of the human cells in 
the spleen and bone marrow of the mice from different cohorts is shown in Figure 16. 
 
 
Figure 16 Final analysis of NSG mice. 
Ten NSG mice, which were transplanted with Jak2*+IKZFΔ6-ERt2 or Jak2*+control vector infected CD34+/CD38-
, CD34+/CD38+ and accordingly unsorted CD34+ cells, were sacrificed for final analysis five month post 
transplantation. The bone marrow and spleen were isolated and the cells were analyzed via flow cytometry, to 
analyze the percentage of human and infected human cells in the spleen and bone marrow. 
It is clearly visible that all mice showed higher percentages of human cells in the bone 
marrow and even higher in the spleen compared to the analysis of the peripheral blood six 
weeks post transplantation. The highest percentage of human cells was found in the mice 
that were transplanted with transduced, unsorted CD34+ cells. The sorted CD34+CD38- and 
CD34+CD38+ cohorts showed comparable engraftment. 
The percentage of transduced human cells in the different cohorts, visualized in Figure 17, 
was very low in the sorted CD34+CD38- and CD34+CD38+ cohorts. All mice that were 
transplanted with unsorted CD34+ cells, in contrast, showed infection of human cells with 
either Jak2* or IKZFΔ6-ERt2 in the spleen and bone marrow. The percentage of Jak2* vector 
transduced cells is much higher in the bone marrow then in the spleen. Despite the fact that 
Jak2* transduction of human cells was not visible in any of the mice before, one mouse even 
showed 25,5% of Jak2* transduction in the BM, as shown in Figure 18. This indicates that 
Jak2* might have an advantage for the infected cells. The higher infection frequencies of the 
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human CD34+ cells with IKZFΔ6-ERt2 was not reflected in the transplanted mice, and most 
mice analyzed had no or very few transduced cells after 5 months. 
 
 
Figure 17 Transduced human cells in BM and spleen. 
The human cells in spleen and bone marrow were analyzed for Jak2* and IKZFΔ6-ERt2 expression. Each column 
represents the human cells of one mouse. Each dot indicates the percentage of Jak2*, IKZFΔ6-ERt2 or 
Jak2*+IKZF-ERt2 expression of these cells. Same color indicates the same cohort. The triangle indicates Jak2* 
expression, whereas the square indicates IKZFΔ6-ERt2 expression. The stars indicate the original infection 
frequency of the bone marrow 
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Figure 18 Percentage of JAK2*-transduced human cells in the bone marrow of mouse #5. 
FACS analysis of the BM cells of mouse #5 that was transplanted with infected, unsorted CD34+ cells shows 
25,5% Jak2* transduced human cells. eGFP stands for Jak2* and venus for IKZFΔ6-ERt2. 
4.1.2 Modeling B-ALL in the mouse system with Jak2* plus IKZFΔ6-ERt2 
Due to the fact that the human CD34+ could not be infected with Jak2* efficiently (due to low 
titers/MOIs and/or an initial negative effect of Jak2* on the cells) and IKZFΔ6-ERt2-infected 
cells were lost in the mice (no long-term engraftment), it was decided to examine the effects 
of mutant Jak2 together with the dominant negative IKZFΔ6-ERt2 in mouse cells as depicted 
in Figure 19.  
 
 
Figure 19 Modeling B-ALL in the mouse system with Jak2* and IKZFΔ6-ERt2 
BM cell were isolated from 129 mice and transduced with the lentiviral Jak2* and the gammaretroviral IKZFΔ6-
ERt2 vector. The transduced cells were finally transplanted into 129 mice. 
Consequently, the bone marrow of five 129 mice was isolated and the lineage negative 
progenitor cells, representing stem cells and early progenitor cells, were enriched using 
MACS columns. The resulting 9x105 cells were infected on day three after BM isolation. 
  56 
 56 
The FACS analysis, shown in Figure 20, clearly shows that the BM cells of the 129 mice, 
which were infected with Jak2* and IKZFΔ6-ERt2, only showed IKZFΔ6-ERt2 infection and 
no Jak2* infection at all. The 129 BM cells only infected with the control vector showed 
infection. The BM cells infected with IKZFΔ6-ERt2 and control vector showed double positive 
cells, control vector infected and IKZFΔ6-ERt2 infected cells. 
 
 
Figure 20 Analysis of the infected bone marrow on the day of transplantation. 
The bone marrow, which was isolated from 129 mice, was infected twice with the Jak2*/control vector and 
IKZFΔ6-ERt2 vector. Analysis of the infected cells was performed on the day of transplantation using flow 
cytometry. The fluorochrome eGFP stands for the Jak2* and control vector, whereas the venus fluorochrome 
stands for the IKZFΔ6-ERt2 vector. 
The corresponding MOI’s and infection frequencies of the cells are presented in Chart 3. The 
MOIs of the lentiviral Jak2* vector and the gammaretroviral IKZFΔ6-ERt2 vector were 
comparable, but the infection frequency with the IKZFΔ6-ERt2 vector was significantly higher 
(36,6%) in comparison to the Jak2* infection frequency (0,5%). Double infection with 
Jak2*+IKZFΔ6-ERt2 vectors was not possible. The lentiviral control vector showed a five 
times higher MOI in comparison to the gammaretroviral IKZFΔ6-ERt2 vector, but its infection 
frequency (8%) was lower by a factor of five compared to the IKZFΔ6-ERt2 infection 
frequency (41%). Only 6% of the cells were double-infected with the control+IKZFΔ6-ERt2 
vector. In conclusion it can be said that the percentage of IKZFΔ6-ERt2 transduced mouse 
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cells was comparable to the percentage of transduced CD34+ cells, but the problem of the 
infection with the lentiviral Jak2* vector was still present. 
 
vector MOI infection frequency 
Jak2*+IKZFΔ6-ERt2 
DP 
Jak2* 
IKZFΔ6-ERt2 
 
 
0,3 
0,42 
 
0% 
0,5% 
36,6% 
control+IKZFΔ6-ERt2 
DP 
control 
IKZFΔ6-ERt2 
 
 
2,26 
0,42 
 
6% 
8% 
41% 
control  
control 
 
2,26 
 
12,2% 
Chart 3 MOI and infection frequency of the 129 murine bone marrow cells. 
The bone marrow cells of the 129 mice were infected twice with the IKZFΔ6-ERt2 plus Jak2* and accordingly 
control vector. The infection frequency of the cells was determined via FACS analysis on the day of 
transplantation. DP stands for “double positive” and indicates the percentage of Jak2*/control+IKZFΔ6-ERt2 
infected cells. 
The infected cells were transplanted into 129 mice, which were lethally irradiated for 21 min 
(=7,6 Gray) on day five after bone marrow isolation, as shown in Chart 4. 
 
vector no. of transplanted mice no. of transplanted cells/mouse 
Jak2*+IKZFΔ6-ERt2 9 (129 mice) 1,36x106 
Chart 4 Transplantation of the infected murine bone marrow. 
The infected bone marrow cells were transplanted into nine mice, transplanting 1,36x106 cells per mouse. 
Peripheral blood was taken six and 15 weeks post transplantation. 
 
Figure 21 Analysis of the peripheral blood six and 15 weeks post transplantation.  
  58 
 58 
The percentage of Jak2*+IKZFΔ6-ERt2, Jak2* only and accordingly IKZFΔ6-ERt2 only expressing cells in the 
peripheral blood of 129 mice is shown six and 15 weeks post transplantation. Every data point presents the 
venus, BFP and accordingly venus+BFP expression value of the peripheral blood of one mouse, which was 
determined via flow cytometry. Every different point shape stands for one mouse six and 15 weeks post 
transplantation. The grey circles stand for mice, which died between the sixth and 15th week post transplantation. 
The black star indicates the original infection frequency with IKZFΔ6-ERt2. 
Figure 21 clearly shows that there were no Jak2* transduced cells in the blood of all mice six 
weeks and 15 weeks post transplantation. The percentage of IKZFΔ6-ERt2 transduced cells 
were again lost over time. Only one mouse still showed an adequate percentage of IKZFΔ6-
ERt2 transduced cells of 18%. The other mice showed IKZFΔ6-ERt2 transduction 
frequencies of between 0,4% and 4,3%.  
4.2 Modeling B-ALL with CRLF2* plus IKZFΔ6 
4.2.1 CRLF2* and IKZFΔ6 in cell culture: colony formation assay 
Due to the fact that Jak2* infection of primary HSC/HPC cells was very inefficient in the two 
previous experiments and the percentage of IKZFΔ6-ERt2 transduced cells was lost over 
time, it was decided to start an in vitro experiment with some changes. First of all, the 
progenitor population was enriched by treating mice with 5-FU for 5 days. Five days was 
chosen, as previous work in the laboratory also showed the enrichment of early B-cell at this 
time point (B. Niebuhr, unpublished results). An IKZFΔ6 vector without fusion to ERt2 was 
used for infection, because if pro-B-cell are infected, an inducible system would not be 
needed. Additionally, CRLF2* was used instead of Jak2* because it is known, as mentioned 
in 1.2.4, that CRLF2 overexpression is found in 7% of BCP-ALL and 10% of these cases 
show CRLF2 mutations. Furthermore, it is known that CRLF2* cooperates with other mutated 
factors to contribute to the formation of haematologic diseases. Additionally, all vectors used 
were based on gammaretroviruses, and ecotropic Env was used as envelope protein, 
instead of lentiviruses with VSV-G proteins. Based on previous experience in the lab, it has 
been determined that the percentage of transduced murine cells are much higher with 
ecotropic Env as envelope then with VSV-G.  
The CRLF2*+IKZFΔ6 double infected cells were analyzed in vitro in a colony formation 
assay, as preliminary study for following mouse experiments. The proliferation behavior and 
growth advantage of CRLF2* plus IKZFΔ6 infected cells in comparison to control vector and 
non-infected HSC/HPC cells was analyzed via a methylcellulose assay. This semisolid 
medium was used due to the fact that B-cell progenitors are able to proliferate and form 
colonies in this medium as a response to cytokine stimulation (mIL-7). Two C57BL/6 mice 
were treated with 5-FU and BM cells of these mice were isolated five days after the start of 5-
FU treatment, as shown in Figure 22.  
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Figure 22 Modeling B-ALL with CRLF2* and IKZFΔ6 in vitro. 
BM was isolated from C57 Ly5.2 mice that were treated with 5-FU for 5 days. The cells were transduced with the 
gammaretroviral CRLF2* + IKZFΔ6 vectors. The transduced cells were then seeded in methylcellulose and 
replated every week for two weeks. 
The cells were cultivated overnight and then infected via retronectin on day one and two after 
isolation with different vectors as shown in Chart 5.  
 
Approaches MOI infection frequency 
CRLF2*+IKZFΔ6 
DP 
CRLF2* 
IKZFΔ6 
 
 
15,2  
14,8 
 
48% 
5,2% 
14,4%:  
CRLF2*+BFP control 
DP 
CRLF2* 
BFP control 
 
 
15,2  
14,8 
 
61,9% 
6,3 % 
9,6%: 
IKZFΔ6+venus control 
DP 
venus control 
IKZFΔ6 
 
 
14,8 
14,8 
 
59,1% 
9,7% 
8% 
Chart 5 Used vectors, corresponding MOI and infection frequencies for the colony assay.  
The cells for the colony assay were infected in three different approaches. The used vectors, the corresponding 
MOI’s and infection frequencies are shown in the chart. DP stands for “double positive”. 
On day three after BM isolation 1x105 infected cells per approach were seeded as triplet in 
methylcellulose. The cells were stained for myeloid and accordingly lymphoid lineage, 
analyzed via flow cytometry and replated in the same cell density on day seven and 14 post 
first seeding in methylcellulose. Lots of colonies were already visible for all approaches after 
seven days and after 14 days.  
Figure 23 clearly shows, that the double infected cells overgrow the single infected and 
uninfected cells in the methylcellulose. The high levels of double infected cells 
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(CRLF2*+IKZFΔ6 or CRLF2*+BFP control or IKZFΔ6+venus control) at the beginning 
resulted in a significantly increased probability that an double infected subclone would 
overtake the cultures. CRLF2* single infection as well as CRLF2*+IKZFΔ6 double infection of 
the cells did not result in a proliferation advantage of the cells. Staining of the cells showed 
that nearly all double positive cells were B220/CD11b positive and therefore do not represent 
B-cells but cells of the myeloid lineage. 
 
Figure 23 Colony assay: The infected cells, grown in methylcellulose, were analyzed via flow cytometry 
on day one, seven and 14 after the second infection.  
The bone marrow cells of two C57BL/6, which were infected twice with CRLF2* and IIKZFΔ6, respectively with 
CRLF2* and BFP control vector, and accordingly with IKZFΔ6 and venus control vector were grown in 
methylcellulose with IL-7(20ng/ml). They were replated every week. The cells were additionally analyzed the day 
after the second infection as well as seven days and 14 days after the second infection. 
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The assumption that the double positive cells did not represent B-cells but cells of the 
myeloid lineage was confirmed using cytospin technology. Looking at the cytospin, shown in 
Figure 24, it became clear that the colonies mainly consisted of monocytes and 
macrophages. 
 
 
Figure 24 Cytospin of the cells of the colony formation assay. 
A cytospin of the cells (after seven days; 1x105 cells/ml), which were infected with CRLF2* and IKZFΔ6 and 
cultured in methylcellulose for one week is shown. The blue arrows indicate macrophages, whereas the red 
arrows indicate monocytes. 
4.2.2 Modeling B-ALL in the mouse system with CRLF2* plus IKZFΔ6 
The chance that the 5-FU enriched stem and progenitors cells differentiate in B-cell direction 
is higher in vivo then in vitro. It was the goal to analyze the contribution of CRLF2*+IKZFΔ6 
to B-ALL formation. Consequently, the previous experiment (4.2.1) was repeated as an in 
vivo experiment, as shown in Figure 25. 
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Figure 25 Modeling B-ALL In the mouse system with CRLF2* and IKZFΔ6 
BM was isolated from C57 Ly5.2 mice that were treated with 5-FU for 5 days. The cells were transduced with the 
gammaretroviral CRLF2* + IKZFΔ6 vectors. The transduced cells were finally transplanted into C57 Ly5.1 mice. 
 
The BM cells were isolated from 14 C57BL/6 CD45.2 mice, which were treated with 5-FU for 
five days. The resulting 9x107 bone marrow cells were cultivated overnight. The cells were 
then infected on day one and two after bone marrow isolation. FACS analysis of the infected 
bone marrow cells on the day of transplantation is shown in Figure 26.  
 
 
Figure 26 FACS analysis of the infected C57BL/6 bone marrow.  
The bone marrow cells of the C57BL/6, which were infected twice, were analyzed via flow cytometry using the 
fluorochromes venus standing for CRLF2*/control and BFP standing for IKZFΔ6/control. There were three 
experimental approaches: CRLF2*+IKZFΔ6, IKZFΔ6+control and CRLF2*+control. The cells were analyzed right 
before transplantation into C57BL/6 CD45.1 mice. 
 
The corresponding MOI’s and infection frequencies are shown in Chart 6. 
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vector MOI infection of the BM 
CRLF2*+IKZFΔ6 
DP 
CRLF2* 
IKZFΔ6 
 
 
0,56 
0,46 
 
41% 
3% 
9% 
IKZFΔ6+venus control 
DP 
venus control 
IKZFΔ6 
 
 
0,6 
0,46 
 
38% 
19% 
2% 
CRLF2*+BFP control 
DP 
CRLF2* 
BFP control 
 
 
0,56 
0,7 
 
35% 
3% 
18% 
Chart 6 MOI and infection frequency of the infected murine bone marrow cells. 
The bone marrow cells of the C57BL/6 mice were infected twice with the IKZFΔ6 plus CRLF2* and accordingly 
control vectors. The infection frequency of the cells was determined via FACS analysis on the day of 
transplantation. DP stands for “double positive” 
The infected cells were transplanted into lethally irradiated C57BL/6 Ly5.1 mice on day three 
after bone marrow isolation, as shown in Chart 7. 
 
vector no. of 
transplanted mice 
no. of transplanted 
cells/mouse 
CRLF2*+IKZFΔ6 15 1,5x106 
IKZFΔ6+venus control 6 1,6x106 
CRLF2*+BFP control 5 1,7x106 
Chart 7 Transplantation of the infected murine bone marrow cells. 
The infected bone marrow cells were transplanted in three different approaches, transplanting between 1,5 and 
1,7x106 cells per mouse. 
 
Peripheral blood of these mice was taken and analyzed five and 11 weeks post 
transplantation. The corresponding percentages of transduced cells are shown in Figure 27. 
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Figure 27 Analysis of the peripheral blood five and 11 weeks post transplantation.  
The percentage of double and single positive cells in the peripheral blood of three different cohorts of C57BL/6 
mice is shown five (1st row) and 11 weeks (2nd row) post transplantation. Starting from left to right, the first cohort 
consists of mice, which were infected with CRLF2* and IKZFΔ6. The second cohort consists of mice, which were 
infected with CRLF2* and a BFP control vector. The third cohort consists of mice, which were infected with 
IKZFΔ6 and a venus control vector. Every data point presents the venus, respectively BFP and accordingly 
venus+BFP expression value of the peripheral blood of one mouse, which was determined via flow cytometry. 
The black stars indicate the corresponding original infection frequency of the BM on the day of transplantation. 
Analysis of the peripheral blood after five weeks showed that the highest percentage of 
transduced cells could be found in the CRLF2*+IKZFΔ6 infected cohort. CRLF2* single 
infected cells showed the highest expression frequency in this cohort with up to 71% positive 
cells. There were also high percentages of double infected cells (up to 33%) visible in this 
cohort. Only IKZFΔ6 expression remained at lower levels. Looking at the CRLF2*+BFP 
control and IKZFΔ6+venus control cohort it became clear that all animals show percentages 
of transduced cells that are below 10%. The only exception was the venus expression in the 
IKZFΔ6+venus control cohort, which had much higher transduction rates at the start.  
Strikingly, the blood analysis six weeks later showed completely different results. The 
percentage of transduced cells dropped in nearly all animals. Only two animals still showed a 
high percentage of CRLF2*+IKZFΔ6 expression, whereas the percentage of CRLF2* 
expression decreased in all animals significantly. Only the percentage of IKZFΔ6 expression 
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remained constant in most animals. This significant decrease of the percentage of 
transduced cells might signify that transduced HSC are being lost. 
Nine animals of the CRLF2*+IKZFΔ6 cohort became sick between day 56 and 103 post 
transplantation and were sacrificed, as depicted in Figure 28. The peripheral blood, bone 
marrow and spleen cells of these mice were analyzed via flow cytometry, as shown in Figure 
29. 
 
 
Figure 28 Survival curve of the transplanted C57BL/6 mice. 
The survival of the mice, which were transplanted with CRLF2*+IKZFΔ6; CRLF2*+control and IKZFΔ6+control 
infected cells, is plotted against the time, presenting the days after transplantation. 
 
 
Figure 29 Infection frequency of the peripheral blood, bone marrow and spleen of the sacrificed mice. 
Peripheral blood, bone marrow and spleen of the sick mice were analyzed. The infection rates were determined 
using flow cytometry. The black stars indicate the original infection frequency of the bone marrow at the day of 
transplantation. Each point shape stands for one mouse. 
It is visible, that all percentages of transduced cells are quite low with the exception of three 
different mice with showed transgene expression frequencies of over 20% in the peripheral 
blood and BM. These mice were analyzed and the results, shown in Chart 8, indicate that the 
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mice did not die because of ALL, but because of diseases such as leukocytosis, 
thrombocytopenia, anemia and unknown reasons. None of the mice possessed an extremely 
large spleen and none of them showed any other signs of ALL. This disease phenotype is 
similar to that observed after induced HSC exhaustion, e.g. after repeated treatments with 
cytotoxins such as 5-FU. 
mouse 
number 
time of death  spleen 
weight  
(mg) 
leukocyte 
count  
(K/µl) 
hematocrit 
(%) 
abnormalities 
#11 56 274 4,54 41,9 Thrombocytopenia 
#13 67 168 7,72 36 none 
#2 67 146 N.D. N.D. none 
#7 70 319 2,74 31,5 Anemia, 
thrombocytopenia 
#6 71 230 14,86 43,6 Leukocytosis, 
thrombocytopenia 
#3 87 132 2,24 52,9 Thrombocytopenia, 
enlarged thymus 
#15 87 311 2,38 34,9 Thrombocytopenia 
#12 101 137 4,1 51,1 Thrombocytopenia, 
polycythemia 
#8 103 249 3,6 40,2 small liver, 
enlarged thymus, 
thrombocytopenia 
Chart 8 Analysis of the sick C57BL/6 mice. 
Sick animals were sacrificed, their peripheral blood was taken, and bone marrow and spleen were isolated. Time 
of death is specified as days post transplantation. The hematocrit is defined as the ratio of red blood cells to the 
total volume of blood.  
4.3 LNK- an additional hit? 
4.3.1 LNK in vitro: overexpression in Ba/F3 cells 
Due to the fact that CRLF2* together with IKZFΔ6 did not show an effect on B-lymphopoiesis 
in the mouse models during the previous experiments, it was decided to look for an 
additional factor that might play a role in the formation of high-risk B-ALL. 
It has been published that there is a function for LNK in limiting B-lymphopoiesis (Takaki et 
al., 2000), presumably by inhibiting JAK2 function. Consequently, we first wanted to analyze 
whether LNK alone and LNK together with CRLF2* has an effect on B-cell progenitor 
proliferation by inhibiting Jak2. The effect of LNK overexpression was first analyzed in cell 
culture. 
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Ba/F3 cells, which represent an early pro-B-cell line, were infected with a LNK expressing 
vector twice to gain cells with LNK overexpression. For these study, IL3-dependent Ba/F3 
and IL3-independent Ba/F3 cells (transduced with CRLF2*-vector) were used. After two 
rounds of infection, infected cells were then selected with puromycin. After infection and 
selection it was tested whether the cells, which were infected with the LNK vector really 
showed a LNK overexpression in comparison to the endogenous Lnk expression in the 
uninfected and control vector infected cells. Western blot analysis was performed to analyze 
the Lnk expression at the protein level. Whole cell lysis, protein extraction and measurement 
of protein concentration of the differently infected and non-infected cells were performed as 
described in 3.2.3.2. 
 
Figure 30 Western blot analysis of Lnk expression in Ba/F3 cells. 
80µg of cell lysates of Ba/F3 cells and accordingly Ba/F3 CRLF2* cells, which were infected with LNK, 
respectively with a control vector, were applied to a 10% SDS gel, separated and plotted onto a PVDF 
membrane. Uninfected Ba/F3 and accordingly uninfected Ba/F3 CRLF2* cells were used as a control as well as 
cells, which were infected with the control vector. The detection of Lnk expression as well as of GAPDH as 
internal control was determined using specific primary antibodies (3.1.7.1) as well as corresponding secondary 
antibodies. 
A polyclonal goat IgG-anti-Lnk antibody was used as primary antibody. LNK could be 
identified as a band at about 65-68 kDa. To be able to compare the signal strength of the 
bands, the blot was also incubated with the primary antibody against the housekeeping gene 
GAPDH. It is clearly visible in Figure 30 that a LNK band was only present for the Ba/F3 cells 
alone and the Ba/F3 cells with CRLF2*, which were infected with the LNK vector and no 
bands were visible for the uninfected and control vector infected cells. The GAPDH bands 
were consistent in all cells. This showed that the LNK vector works and LNK overexpression 
was present in the LNK vector infected cells. 
 
 
 
 
  68 
 68 
4.3.2 Competition assay  
 
Figure 31 Competition assay 
Ba/F3 cells were infected with the LNK vector and accordingly BFP control vector. They were mixed with 
uninfected Ba/F3 cells and analyzed via FACS every 2-3 days. 
To see the effect of the confirmed LNK overexpression in cell culture a competition assay 
between the LNK overexpressing, control vector expressing and uninfected cells was 
performed. Two different kinds of Ba/F3 cell lines were used again to study the role of LNK 
overexpression in these cells: Ba/F3 alone and Ba/F3 cells with CRLF2*. The experiment 
was performed twice, as shown in Figure 31. The Ba/F3 cells, which present murine bone 
marrow derived pro-B-cells, were infected with the LNK vector and accordingly the control 
vector via spinoculation on two days one after another during both experiments. The 
corresponding MOI’s and infection frequencies after puromycin selection are shown in Chart 
9. A puromycin selection of the cells was performed directly after the second infection, by 
adding puromycin at a concentration of 1µg/ml to the cells because the infection rates were 
too low. After the second infection only 2,2% of the cells were LNK vector positive and 7,7% 
of the cells were control vector positive, which increased to close to 100% after puromycin 
selection. 
vector Infection frequency 
after puromycin 
selection 1st 
experiment 
Infection frequency 
after puromycin 
selection 2nd 
experiment  
LNK 98,2% (Ba/F3) 
98,4% (Ba/F3+CRLF2*) 
99% (Ba/F3) 
97% (Ba/F3+CRLF2*) 
control 97,8%(Ba/F3) 
94,1%(Ba/F3+CRLF2*) 
96% (Ba/F3) 
94% (Ba/F3+CRLF2*) 
Chart 9 Competition assay: infection frequencies of the Ba/F3 cells. 
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The Ba/F3 cells were infected twice with a Lnk vector and accordingly a control vector at MOI’s of between 0,4 
and 2,3. Puromycin was added twice over period of four days at a concentration of 1µg/ml. The puromycin 
selection resulted in infection frequencies of between 94% and 99%. 
To analyze the effect of LNK on the proliferation behavior of pro-B-cells in comparison to the 
proliferation of control vector-transduced cells or uninfected cultures, a competition assay 
with the two different cells lines was performed. The BFP positive cells, representing the cells 
containing the LNK vector or the control vector, were mixed with the corresponding 
uninfected cells at a ratio of about 70:30 infected to uninfected cells. The proliferation of the 
cells was analyzed via flow cytometry every two to three days for 12 days.  
Concerning the Ba/F3 cell line, cultured with IL-3, it is visible in both experiments that the 
cells with LNK overexpression show a constant decrease in proliferation in comparison to the 
cells containing no vector over the whole 12 days of measurement, as shown in Figure 32. In 
contrast the cells containing the control vector show a slight increase in proliferation at the 
beginning of measurement followed by a mainly constant percentage distribution in 
comparison to the cells without any vector. 
 
 
Figure 32 Competition assay of Ba/F3 cells, which overexpress LNK and were cultured with IL-3. 
Determination of relative BFP expression of the cells, which were infected with either the LNK vector or the 
control vector. FACS analysis was performed every 48-72 hours. 
Looking at the Ba/F3 cells with CRLF2*, which were grown without IL-3, it is visible that the 
cells show a completely different proliferation behavior. It is shown in Figure 33 that cells with 
LNK overexpression as well as the control vector infected cells show no significant difference 
in their proliferation behavior. The cell number of the differently infected cells nearly stayed 
constant overtime as well as the cell number of the uninfected cells. These results show that 
whereas LNK inhibits IL3-mediated proliferation, it does not inhibit proliferation stimulated by 
CRLF2*. 
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Figure 33 Competition assay: LNK overexpression in Ba/F3 cells, already containing CRLF2*. 
Determination of the percentage of BFP positive cells, which were infected with either the LNK vector or the 
control vector. FACS analysis was performed every 48-72 hours. 
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5 Discussion 
The aim of this thesis was to optimize a mouse model system to analyze the effects of 
mutated kinases and transcription factors, such as Jak2* and IKZFΔ6, on B-cell development 
in vivo. The reasons for developing such a model system are two-fold: 1) It allows the testing 
of the hypothesis that mutations that provide a proliferative stimulus coupled with mutations 
that inhibit differentiation are required (but not necessarily sufficient) to induce a leukemia; 
and 2) it provides an in vivo system to test the efficacy of small kinase inhibitors that target 
the proliferative stimulus of the mutated kinase. 
To establish this model, a retroviral transduction, stem cell transplantation approach was 
taken, first using human primary HSC/HPC and then mouse primary HSC/HPC. Although the 
work presented here was not able to establish such a model system, insights into the 
problematic of this approach were obtained and will be discussed. In addition, suggestions 
for improving this approach, for instance by targeting other signaling pathways, are 
presented. 
5.1 Retroviral transduction of Jak2* in primary cells is problematic for modeling B-
ALL in mice 
The double infection of human CD34+ cells with the concentrated lentiviral Jak2* vector 
particles packaged with VSV-G and with the gammaretroviral IKZFΔ6-ERt2 vector packaged 
with ecotropic Env, resulted in up to 60% of venus expressing (IKZFΔ6-ERt2) target cells, but 
at most 2% of Jak2* transduced cells. Similarly, analysis of the peripheral blood six weeks 
post transplantation showed rarely any single or double-transduced human CD34+ cells 
either. Final analysis of the sacrificed mice 5 month post transplantation showed that there 
were single IKZFΔ6-ERt2 or Jak2* transduced human cells within the spleen and bone 
marrow, but never as double positive cells. The problem that we could not get any double 
infection of the human CD34+ cells as well as of the murine BM cells started with the 
transduction protocol. 
Previous experiments in our lab had shown that Jak2* vectors based on gammaretroviral 
vectors had very poor titers when tested on murine SC-1 fibroblasts, whereas much better 
vital titers were obtained when Jak2* was expressed via a lentiviral vector pseudotyped with 
VSV-G as envelope protein. Furthermore, it has been shown that the titers of the vector 
containing the murine Jak2* were significantly higher then the titers of vectors, containing the 
human Jak2*. Additionally, it is possible to concentrate lentiviral particles packaged with 
VSV-G via ultracentrifugation, whereas gammaretroviruses packaged in the less stable 
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ecotropic Env, loose infectivity during this process. Consequently, Jak2* viral supernatants 
were always produced as lentiviruses, exposing VSV-G, and were concentrated.  
The titer determination on SC-1 cells during this work showed that the lentiviral mJak2* titers 
(max. 9x105 gtu/ml) were at best only half as high as the gammaretroviral IKZFΔ6-ERt2 titers 
(max. 2x106 gtu/ml). The low titers of the lentiviral Jak2* vector in comparison to the 
gammaretroviral IKZFΔ6-ERt2 vector resulted in lower MOIs of the lentiviral Jak2* vector 
then needed, despite the fact that Jak2* was concentrated. 
In experiments in which human CD34+ cells were infected, the MOIs of the lentiviral Jak2* 
vector packaged in VSV-G were about one third lower then the MOIs of the gammaretroviral 
IKZFΔ6-ERt2 vector packaged with ecotropic Env, as shown in Chart 1. We used 
comparable MOIs of the lentiviral Jak2* and the gammaretroviral IKZFΔ6-ERt2 vector for the 
infection of murine bone marrow cells (Chart 3). Nevertheless this infection resulted in only 
0,5% Jak2* positive cells and 36,6% IKZFΔ6-ERt2 positive cells. Additionally, the MOI of the 
IKZFΔ6-ERt2 vector during the infection of the murine BM cells was one-fifth that of the MOI 
of the lentiviral control vector, but 60% of the cells expressed venus (IKZFΔ6-ERt2) and only 
8% eGFP (control vector). This indicates that regardless whether human or murine primary 
cells are infected, the lentiviral constructs need much higher MOIs for high percentages of 
transduced target cells in comparison to the gammaretroviral constructs. Consequently, the 
MOI of Jak2* was too low for the transduction of target cells with a lentiviral construct in both 
experiments.  
It is important to note that for the gammaretroviral constructs, ectotropic Env was used to 
mediate cell entry. This entry system appears to be much more efficient in haematopoietic 
cells than VSV-G mediated cell entry, whereas in SC1 fibroblasts, the system used to titer 
the viral vectors, no noticeable difference is observed. Whether this reflects differences in 
expression levels of cellular receptors used by the viruses in the two cell types, or higher 
sensitivity to the known cytoxicity of VSV-G glycoproteins is not clear. Although several 
MuLV Env proteins (including ecotropic Env) can be used to pseudotype lentiviral vectors, 
the titers are generally much lower. It would be of interest to try other viral glycoproteins for 
packaging of the lentiviral vectors (e.g. LCMV; Cocal) (Bhella et al., 1998; Beyer et al., 2002; 
Trobridge et al., 2010). 
Additionally, the Jak2* vector presents a really large construct. The Jak2* viral vector is ca 
9.5 kb in size. In contrast, the gammaretroviral vectors, such as CRLF2* (ca 4.6 kb), IKZFΔ6-
ERT2 (5.3 kb) and LNK (7.3 kb) were smaller in size and led to higher percentages of 
transduced target cells. The large size of the Jak2* vector might contribute to the fact that the 
titers were always low due to poor packaging efficiencies.. 
Another important fact to mention is that the Jak2* virus was concentrated before infecting 
the human and murine primary cells, because of the relatively low titers. The proteins of the 
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serum were also concentrated during this process and, consequently, might be toxic for the 
primary cells, but not for the more robust SC-1 cells during titer determination. Supernatants 
from the virus producers may also produce large quantities of the VSV-G protein, which are 
known to be cytotoxic. 
This toxicity, the large size of the vector and the relatively low MOI could be reasons for the 
problems of infecting primary cells. Another possibility that we cannot rule out is that early 
HSC/HPC may be sensitive to high expression levels of activated Jak2*, leading to 
differentiation or death of the cells. 
5.2 Optimization of the conditions for the xenograft model 
The aim of the in vivo experiment using CD34+ cells (4.1.1) was to compare different 
experimental settings to optimize a xenograft model for B-ALL. Three different cell 
populations were compared for this experiment: sorted CD34+CD38- (most primitive cells), 
sorted CD34+CD38+ (later progenitor population) and unsorted CD34+ (used in previous 
experiments) cells.  
Nearly twice the number of CD34+ cells was thawed for the sorted approach (3x107 cells) in 
comparison to the unsorted approach (1,6x107 cells). But as a result of sorting only one 
seventh (CD34+CD38+) and accordingly one twelfth (CD34+CD38-) of sorted cells were 
infected in comparison to the unsorted CD34+ cells. Additionally, only 4,3x104 (CD34+CD38-
) and 6x104 (CD34+CD38+) cells/mouse were transplanted for the sorted approach in 
comparison to 1,2x106 cells/mouse, which were transplanted for the unsorted approach. 
Looking at the engraftment (Figure 16) of the three approaches, it is clearly visible that the 
engraftment of human cells was much better in the unsorted CD34+ cell approach. The mice, 
which were transplanted with the infected and unsorted CD34+ cells, showed up to 71% of 
human cells in the bone marrow compared to a maximum of 16% (CD34+CD38-) and 21% 
(CD34+CD38+) of human cells in the bone marrow of the mice, transplanted with the sorted 
populations. On the one hand, the worse engraftment of the sorted populations is probably 
the result of stress of the sorted cells due to sorting and to the infection on day zero and one. 
The unsorted population did not experience that stress, because it was not sorted and was 
infected on day one and two. This stress resulted in less proliferation and the following low 
cell density was not the ideal condition for the sorted CD34+CD38- and CD34+CD38+ 
populations. On the other hand, the i.v. injection might not be the ideal form of injection for 
the sorted cells. During i.v injection the place of injection is quite far away from the target 
niche of the stem cells in the bone marrow. As a result, the low number of the sorted cell 
population might not be able to find their niche. Consequently, intra-femoral injection, what 
leads to injection of the cells near the niche, might be a better alternative for the injection of 
the sorted populations (McKenzie et al., 2005). 
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The transgene transduction frequencies (Figure 17) of the human cells were also much 
higher in the unsorted CD34+ population, with up to 33% of venus (gammaretroviral IKZFΔ6-
ERt2, RD114 env) expression and 25,5% eGFP (concentrated lentiviral Jak2*, VSV-G) 
expression compared to a maximum of 2,6% eGFP expression (CD34+CD38-) and 1,2% of 
venus (gammaretroviral IKZFΔ6-ERt2, RD114 env) expressing CD34+CD38+ cells. But by 
looking at the IKZFΔ6-ERt2 expression frequencies before transplantation and after five 
month it is visible that also the unsorted, infected human cells were lost selectively over time. 
The worse infection frequencies of the sorted populations were probably the result of the lack 
of proliferation of these cells. Despite the fact that lentiviruses are known to also infect non-
proliferating cells, no infection of the sorted cells with Jak2* (lentivirus) was visible. Double 
positive cells were present in none of the cohorts probably due to the reasons mentioned in 
5.1.  
Consequently the xenograft model needs to be optimized by infecting and transplanting a 
higher number of the sorted, early progenitors CD34+CD38-. The problem was that these 
cells did not proliferate. Consequently, a much higher cell number of CD34+ should be 
thawed. The infected cells should then be injected intra-femoral to improve the homing and 
engraftment of the sorted populations 
Alternatively, the next approach could be the infection of unsorted CD34+ cells on day one 
and two after thawing with gammaretroviral vectors that are pseudotyped with RD114 Env 
such as CRLF2*+IKZFΔ6, instead of the lentiviral Jak2* vector. 
5.3 Optimization of the in vitro assay 
Murine bone marrow cells were double infected with two gammaretroviral vectors, 
expressing CRLF2* and IKZFΔ6, and seeded in methylcellulose with rmIL-7 to analyze the 
effect of CRLF2* and IKZFΔ6 on B-cell proliferation and colony forming ability in vitro.  
A cytospin showed that the CRLF2*+IKZFΔ6 infected bone marrow cells differentiated into 
the myeloid direction and mainly formed colonies of macrophages and monocytes, as shown 
in 4.2.1. FACS analysis of the cells confirmed this finding. This kind of differentiation 
happened although the bone marrow cells were cultured with rmIL-7 in methylcellulose, what 
normally drives differentiation into the B lineage direction (Kikuchi et al., 2008). But the 
problem was that rmIL-7 was not used from the beginning. The bone marrow cells were 
isolated from the mice five days after 5-FU treatment, cultured in SFEM with the whole 
cytokine cocktail (rhFlt3, rhIL11, rmSCF, rmIL3) for two days during infection and were then 
seeded in methylcellulose with rmIL-7 only. These two days in culture with the complete 
cytokine cocktail probably drove the differentiation of the progenitor cells in direction of the 
myeloid lineage. To analyze the effects of CRLF2*+IKZFΔ6 on B-cell proliferation and colony 
  75 
 75 
forming ability in vitro rmIL-7 should be used from the beginning, right after bone marrow 
isolation to repress differentiation in the myeloid direction. 
Another problem of the colony formation assay was that all double infected cells, 
independent of the vector combination, showed a proliferation advantage in comparison to 
the single infected and uninfected cells. Figure 23 clearly shows that the double infected cells 
overgrow the single infected and uninfected cells in the methylcellulose. The high levels of 
double infected cells (CRLF2*+IKZFΔ6 or CRLF2*+BFP control or IKZFΔ6+venus control) at 
the beginning resulted in a significantly increased probability, that a double infected subclone 
would overtake the cultures. CRLF2* single infection as well as CRLF2*+IKZFΔ6 double 
infection of the cells did not result in a proliferation advantage of the cells. To prevent too 
high infection frequencies the cells should be infected just once and should then directly be 
seeded into methylcellulose. 
Due to the fact that the CRLF2* single infected cells did not establish themselves and did not 
lead to B-lineage differentiation it became clear that CRLF2* alone is not able to promote the 
expansion of the cells and is not strong enough to have an significant influence on B-cell 
development and differentiation in this assay, as (Roll and Reuther, 2010) had already 
postulated. 
Nevertheless, with some changes, as the cultivation with rIL-7 from the beginning and the 
prevention of too high infection frequencies, the colony assay seems to be a good 
preliminary study for possible following mouse experiments. But these assays also 
demonstrated the difficulties of assaying primary cells in culture, due to inherent fluctuations 
in cell proliferation of single clones and maintenance of B-cell differentiation, even under 
optimal B-cell conditions 
5.4 Murine model using CRLF2* and IKZFΔ6 
5.4.1 CRLF2* transduction is more efficient 
In the experiment 4.2.2, the lentiviral Jak2* vector was replaced by a gammaretroviral 
CRLF2* vector to circumvent the problems mentioned in 5.1. This CRLF2* vector showed 
higher titers (CRLF2*: 1,5-2,9x106 gtu/ml; Jak2*: 9x105 gtu/ml) on SC-1 cells during titration 
and was smaller in size in comparison to the Jak2* vector.  
The MOIs of the used vectors IKZFΔ6 (MOI:0,46) and CRLF2* (MOI:0,56) were comparable 
and the resulting percentage of double positive bone marrow cells was much higher then in 
the previous experiments. 41% of the bone marrow cells were double positive, 9% expressed 
IKZFΔ6 only and 3% showed CRLF2* expression. This showed that using CRLF2* instead of 
Jak2* and gammaretroviruses instead of lentiviruses improved the percentage of double 
positive bone marrow cells significantly. 
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5.4.2 5-FU progenitor enrichment results in fewer long-term HSC 
Looking at the analysis of the peripheral blood five and 11 weeks post transplantation, 
depicted in Figure 21, it becomes clear that the percentage of transduced cells decreased 
significantly in nearly all animals over time. Five weeks post transplantation between 0,4% 
and 23% (one case 92%) of the blood cells were double positive, 3%-53% showed CRLF2* 
expression and 0,6%-18% IKZFΔ6 expression. Eleven weeks post transplantation only two 
animals still showed a high number of CRLF2*+IKZFΔ6 positive cells, whereas CRLF2* 
positive cells decreased in all animals significantly. The transduced cells (single and double 
positive) did not benefit from the transgene expression and did not show an enhanced 
proliferation. This rather negative selection leads to the loss of the infected cells over time 
unless another mutation occurs, which leads to an enrichment of the cells. 
Additionally, the treatment of the mice with 5-FU for five days resulted in a heterogeneous 
population of cells in the bone marrow (Ogawa et al., 1994). The isolated bone marrow cells 
probably still contained lots of ST-HSCs and progenitor cells and not only LT-HSCs. These 
ST-HSCs and progenitor cells are probably easier to infect, which might result in the high 
infection frequencies of the bone marrow right before transplantation. These cells then 
differentiate in the mice and are lost.  
In summary we found out that using the combination of 1) CRLF2* as transgene in 
comparison to Jak2*, 2) only gammaretroviral vectors with ecotropic Env instead of 
lentiviruses with VSV-G, and 3) comparable MOIs worked much better for double-infecting 
murine primary cells. We speculate that the infection of the ST-HSCs and progenitor cells 
instead of LT-HSCs, followed by the take over of the niche by these cells and the loss of 
stem cells due to expression of either CRLF2* or IKZFΔ6 or both, resulted in “stem cell 
exhaustion” and death of the mice.  
5.4.3 CRLF2* and IKZFΔ6 do not synergize to induce ALL 
The fact that none of the mice died of acute lymphoblastic leukemia indicates that the double 
negative IKZFΔ6 was not strong enough as second hit to cause ALL together with CRLF2*. 
But by looking at Figure 27 and Figure 28 it is visible that the CRLF2* together with IKZFΔ6 
seem to have an effect on the cells. The percentage of transduced bone marrow cells was 
comparable in all cohorts before transplantation. But analysis of the peripheral blood after 
five weeks showed that the control cohorts (control+CRLF2*; control+IKZFΔ6) showed much 
less double positive as well as CRLF2* single positive cells in comparison to the 
CRLF2*+IKZFΔ6 cohort. Additionally, nine out of ten mice that became sick were of the 
CRLF2*+IKZFΔ6 cohort. Consequently, CRLF2* and IKZFΔ6 seem to synergize, but they are 
not strong enough to induce B-ALL formation. Probably an additional mutation is necessary 
for B-ALL induction. 
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To further improve the B-ALL model another mouse model should be used, in which 
leukemia can be induced. Consequently, a knock-out mouse, in which a tumor suppressor 
gene is deleted, would be an alternative to the C57BL/6 BM cells. Furthermore, the search 
for an additional hit next to CRLF2* and IKZFΔ6 would increase the chances of modeling B-
ALL in mice. 
5.5 LNK is able to inhibit IL-3 mediated pro-B-cell proliferation in vitro 
A minimum of two mutations are generally thought necessary for the transformation of a 
stem cell or progenitor cell to a leukemic cell (Dash and Gilliland, 2001). We have chosen 
CRLF2* and IKZFΔ6 for our experiments, as they occur together at a high incidence of high-
risk B-ALL. This work provided evidence that CRLF2* and IKZFΔ6 synergize but do not 
induce B-ALL. The mice, which were transplanted with CRLF2*+IKZFΔ6 infected cells, did 
not establish B-ALL although nine of them died but due to other diseases and reason. This 
demonstrates that CRLF2* together with IKZFΔ6 does not contribute to B-ALL formation in 
our mouse model. Consequently, we chose Lnk as additional hit, due to the fact that Lnk 
plays a role in haematopoeisis and B-cell differentiation (Takaki et al., 2000; Takaki et al., 
2002)  
It has been shown that IL-3 mediated signaling happens via the Jak2 kinase (Hara and 
Miyajima, 1996) and my experimental data (4.3.2) showed that LNK overexpression in the 
presence of IL-3 significantly inhibits the proliferation of pro-B-cell line Ba/F3, presumably 
through inhibiting Jak2. In the absence of IL-3 and together with CRLF2* there was no effect 
visible on the proliferation behavior of the pro-B-cells, suggesting that TSLP may signal 
through other pathways and kinases. Thus the high levels of pro-B- and pre-B-cells in Lnk-/- 
mice may not be due to inhibition of the TSLP or IL7 pathways, but perhaps via the preBCR 
and BCR pathway and associated kinases. This is supported by the fact that Lnk is present 
during all stages of B-cell differentiation, whereas CRLF2 and IL7Ra are not. But the 
opinions about the TSLP mediated signaling are still controversial. On the one hand, it has 
been postulated that TSLP mediated phosphorylation of the STATs happens independently 
of JAK proteins (Isaksen et al., 1999; Levin et al., 1999). On the other hand, it has been 
postulated that in primary T-cells TSLP uses a combination of Jak1 and Jak2 to induce 
STAT5 activation (Rochman et al., 2010). They showed that Jak1 is associated with the 
IL7Rα chain and Jak2 with the TSLPR and that Jak1 and Jak2 are essential for TSLP 
induced signaling and STAT5 phosphorylation. 
Because LNK overexpression showed an effect on IL-3 mediated pro-B-cell proliferation in 
vitro in my experiment, the next aim would be to investigate the effects of LNK in vivo. 
Consequently it would be interesting to analyze the effects CRLF2* and IKZFΔ6 together in 
Lnk knock-out mice. In support of this approach, very recent studies have indeed uncovered 
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LNK inactivation mutations in B-ALL in conjunction with CRLF2 activating mutations (Roberts 
et al., 2012). 
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